   
Document Type:  Protocol  
Official Title:  LowEr Administered Dose with highEr Relaxivity: Gadovist vs 
Dotare m (LEADER 75 ) 
NCT N umber:  [STUDY_ID_REMOVED]  
Document D ate: 26 MAR 2019  
 
Clinical Study  Protocol
No. BAY No. 86-4875 / IMPACT no.19773
26 March 2019    Version no. 2.0 Page: 1of 60
Cover page of the integrated protocol
LowEr Administered Dose with highE r Relaxivity : Gadovist vs Dotarem (LEADER 75)
This protocol version is an integration of the following documents / sections:
Original protocol, Version 1.0, dated 23 JAN 2018
Amendment no. 1(described in Section 15) forming integrated protocol Version 
2.0, dated 26MAR 2019
Amendments not included in the consecut ive numbering of amendments are local 
amendments not forming part of this integrated global protocol
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 2of 60
1. Title page (AMENDED)
LowEr Administered Dose with highE r Relaxivity : Gadovist vs Dotarem (LEADER 75)
Test drug: BAY No. 86-4875/ Gadobutrol / (GADOVIST)
Study  purpose: Comparison of Gadovist 75% standard dose to Dotarem at full 
standard dos e
Clinical study  phase: 4 Date: 26MAR 2019
Registration: EudraCT:  2018-000690-78 Version no.: 2.0
Sponsor’s study  no.: IMPACT no . 19773
Sponsor: a)Sponsor (Non- US): Bay er AG, D -51368 Leverkusen, 
German y
b)Sponsor (US territory ): Bay er HealthCare 
Pharmaceuticals Inc., 100 Bay er Boulevard, 
P.O. Box 915, Whippany  NJ 07981- 0915, USA
Sponsor’s medical 
expert:MRI  Special Indications & Support
Bayer HealthCare Pharmaceuticals Inc., 100 Bay er Boulevard, 
P.O. Box 915, Whippany  NJ 07981- 0915, USA
The study  will be conducted in compliance with the protocol, ICH- GCP and any  applicable 
regulatory  requirements.
Confidential
The information provided in this document is strictly  confidential and is intended solely  for 
the guidance of the clinical investigation . Reproduction or disclosure of this 
document - whether in part or in full - to parties not associated with the clinical 
investigation or its use for any  other purpose without the prior written consent of the 
sponsor is not permitted.
Throughout this document, symbols indicating proprietary names ( , TM) may not be displayed . 
Hence, the appearance of product names without these symbols does not imply that these names 
are not protected .
PPD
PPD
Clinical Study Protocol 
No. BAY No. 86-4875 / IMPACT no. 19773 
26 MAR 2019 Version no. 2 Pagc:3ol'61 
Signature of the sponsor's medically responsible person 
The signatory agrees to the content of the final clinical study protocol as presented. 
Name:  Role: 
Signature:  
PPD
PPD
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 4of 60
Signature of principal investigator
The signatory  agrees to the content of the final clinical study  protocol as presented.
Name: __________________________________________                      
Affiliation: __________________________________________
Date: Signature:
Signed copies of this signature page are stored in the sponsor’s study  file and in the respective 
center’s investigator site file.
In the protocol document, this page may remain unsigned.
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 5of 60
2. Synopsis
Title LowEr Administered Dose with high Er Relaxivity: Gadovist vs Dotarem 
Acronym LEADER 75
Clinical study phase Phase 4
Study objective(s) The prim ary objectives of this study are to dem onstrate:
Noninferiority of gadobutrol (0.075 mmol/kg BW) compared to gadoterate 
(0.1 mmol/kg BW) based on a blinded read for: 
Degree of contrast enhancement 
Assessment of border delineation 
Internal morphology of lesions
The secondary objectives of this study are to:  
Dem onstrate non -inferiority for number of lesions
Confidence in diagnosis
Com pare the 0.075 mmol/kg BW dose of gadobutrol to standard 
dose gadoterate (Dotarem )for:
oT1w MRI image quality in a paired comparison
oSensitivity/Specificity for presence of malignant disease
versus the final clinical diagnosis.
Com pare the overall contrast enhancement of gadobutrol 
(0.075 mmo l/kg BW) to the standard dose of gadoterate 
0.1mmol/kg) for steady -state CNS imaging. Quantitative contrast 
enhanc ement will be performed using an exploratory Overall 
Contrast Enhancement Estimation Algorithm . 
Assess the safety profile of the reduced dose of 0.075 mmol/kg 
BW of gadobutrol and standard dose gadoterate after IV 
admi nistration
Test drug(s) gadobutrol (Gadovist®/Gadavist®) 1.0 molar
Nam e of active ingredient gadobutrol
Dose(s) 0.075 mmol/kg
Route of administration IV
Duration of treatm ent single dose
Reference drug(s) gadoterate (Dotarem®/Clariscan™) 0.5 molar
Nam e of active ingredient gadoterate
Dose(s) 0.1 mmol/kg
Route of administration IV
Duration of treatm ent single dose
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 6of 60
Indication Contrast -enhancement in MRI of the central nervous system (CNS) for the 
detection/visualization of areas with normal and disrupted blood brain 
barrier (BBB) and/or abnormal vascularity
Diagnosis and main criteria for inclusion /exclusionAdult patients with known or highly suspected CNS pathology referred for
contrast -enhanced MRI of the CNS based on current clinical symptoms or 
on a previous imaging procedure.
Study design Open label multi -center com parative, cross -over trial open to adult patient s 
with known or highly suspected of having CNS pathology refer red for 
imaging of the CNS. 
Methodology Two CNS MRIs will be obtained for each enrolled patient:  
Unenhanced MRI consisting of steady -state sequences 
(T1-weighted, T2 -weighted, and FLAIR) and gadoterate -enhanced 
MRI consisting of steady -state sequence ( T1-weighted)
Unenhanced MRI consisting of steady -state sequences 
(T1-weighted, T2 -weighted, and FLAIR) and gadobutrol -enhanced 
MRI consisting of steady -state sequence (T1 -weighted)
The unenhanced MRI, combined unenhanced and gadoterate -enhanced 
MRI, and the unenhanced, and the combined unenhanced and gadobutrol -
enhanced MRI will be evaluated by 3 independent blinded readers for the primary efficacy endpoints . 
The investigator will note the referring diagnosis, and identify the size and 
location of the enhancing lesion which makes the subject eligible for study inclusion . The investigator w ill also provide the final clinical diagnosis and 
whether this represents malignant disease . The final clinical diagnosis will 
be based on all available clinical informa tion up to 30 days after the first 
MRI .
All AEs from the si gning of informed consent will be recorded. Safety will 
be assessed using data from treatment emergent adverse events (TEAEs). 
Type of control Gadoterate- enhanced MRI
Number of patient s Total: 180 enrolled patients
Minimum per center: N/A    Maximum per center:~ 20
Prim ary variable(s) The 3primary efficacy variables (visualization parameters) are:
the degree of lesion contrast enhancement, 
assessment of lesion border delineation, and 
interna l morphology of lesions
Time point/fram e of 
measurement for prim ary 
variable(s)The primary variable requires completion of a blinded read, done in three
sessions
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 7of 60
Plan for statistical analysis Co-prim ary target variable(s):
Lesion contrast enhancement
Lesion border delineation
Lesion internal morphology
Up to 5 of the largest lesions will be selected and scored using a 
pre-specified scale by the blinded readers.
The related statistical hypotheses read as follows:
H0: (gadobutrol -gadoterate) ≤ -0.2*(gadoterate –unenhanced) 
vs. 
K0H1:(gadobutrol –gadoterate ) > -0.2*(gadoterate –
unenhanced)
The study is considered successful if all 3 hypotheses related tothese co -
primary target variables c an be rejected at a one- sided alpha of 0.025, 
which will be equivalent to a two -sided alpha of 0.05 .
Rejection of such a hypothesis means that it is demonstrated that gadobutrol 
(Gadovist )at reduced dose preserves at least 80% of the effect gadoterate 
(Dotarem )as compared to unenhanced images.
Enrolling 180 subjects allow s for approximately 25% of non -evaluable 
patients ,and guarantees 90% pow er for border delineation . For the 
remaining two variables the pow er will be close to 100% w ith this sample 
size. Hence ,the overall pow er of this study will be at least 90%.
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 8of 60
Table of contents
1. Title page (AMENDED).................................................................................................... 2
Signature of the sponsor’s medically responsible person ..................................................... 3
Signature of principal investigator ......................................................................................... 4
2.Synopsis .............................................................................................................................. 5
Table of tables ......................................................................................................................... 10
Table of figures ....................................................................................................................... 10
List of abbreviations and Definitions of terms .................................................................... 11
3. Introduction ..................................................................................................................... 13
4.Study objectives ............................................................................................................... 13
4.1 Primary  objectives ......................................................................................................... 13
4.2 Secondary  objectives ..................................................................................................... 13
5.Study design..................................................................................................................... 14
5.1 Design overview ............................................................................................................ 14
5.2 Primary  variable(s) ......................................................................................................... 15
5.3 Secondary  efficacy  variables ......................................................................................... 15
5.4 Justification of the design .............................................................................................. 15
5.5 End of study ................................................................................................................... 16
5.6 Primary  objectives ......................................................................................................... 16
5.7 Primary  completion ........................................................................................................ 16
6.Study population ............................................................................................................. 16
6.1 Eligibility ....................................................................................................................... 16
6.2 Inclusion criteria ............................................................................................................ 17
6.3 Exclusion criteria ........................................................................................................... 17
6.4 Justification of selection criteria .................................................................................... 18
6.5 Recruitment .................................................................................................................... 18
6.6 Withdrawal of patients from study ................................................................................ 19
6.6.1 Withdrawal ................................................................................................................. 19
6.6.2 Replacement ............................................................................................................... 20
6.7 Patient identifi cation ...................................................................................................... 20
7.Treatments ....................................................................................................................... 20
7.1 Treatments to be administered ....................................................................................... 20
7.1.1 Gadobutrol .................................................................................................................. 20
7.1.2 Gadoterate treatment ................................................................................................... 21
7.2 Dosage and administration............................................................................................. 21
7.3 Identity of study  treatment ............................................................................................. 21
7.4 Blinding.......................................................................................................................... 22
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 9of 60
7.5 Drug logistics and accountability ................................................................................... 22
7.6 Treatment compliance .................................................................................................... 22
8.Non-study therapy ........................................................................................................... 22
8.1 Prior and concomitant therap y....................................................................................... 22
8.2 Post-study  therapy .......................................................................................................... 23
9.Procedures and variables ................................................................................................ 23
9.1 Tabular schedule of evaluations ..................................................................................... 23
9.2 Study  periods ................................................................................................................. 26
9.2.1 Baseline stud y period 1 ............................................................................................... 26
9.2.2 Study period 1 ............................................................................................................. 26
9.2.3 Baseline stud y period 2 ............................................................................................... 27
9.2.4 Study  period 2 ............................................................................................................. 27
9.2.5 Post-Injection phone contact ....................................................................................... 27
9.2.6 Final clinical diagnosis ............................................................................................... 28
10.Procedures and variables ................................................................................................ 28
10.1 Population characteristics .............................................................................................. 28
10.1.1 Demographic ............................................................................................................... 28
10.1.2 Medical history ........................................................................................................... 29
10.1.3 Prior and concomitant medications ............................................................................ 29
10.2 Efficacy .......................................................................................................................... 29
10.2.1 MRI  procedures .......................................................................................................... 29
10.3 Pharmacokinetics ........................................................................................................... 34
10.4 Safety ............................................................................................................................. 34
10.4.1 Adverse events ............................................................................................................ 34
10.5 Prospective blinded image evaluation and centralized procedures................................ 39
10.5.1 Image handling and preparation ................................................................................. 39
10.5.2 Blinded reading evaluations ....................................................................................... 4010.5.3 Technical prerequisites for blinded readings .............................................................. 41
10.5.4 Randomization of image material ............................................................................... 42
10.6 Appropriateness of procedures and measurements ........................................................ 43
11.Statistical methods and determination of sample size ................................................. 43
11.1 General considerations ................................................................................................... 43
11.2 Statistical and analy tical plans ....................................................................................... 43
11.2.1 General considerations................................................................................................ 43
11.3 Analy sis sets ................................................................................................................... 44
11.3.1 Definition of efficacy  analy sis set .............................................................................. 44
11.4 Variables and planned statistical anal yses..................................................................... 44
11.4.1 Primary  efficacy  variables .......................................................................................... 44
11.4.2 Secondary  efficacy  variables ...................................................................................... 46
11.5 Determination of sample size ......................................................................................... 47
12. Data handling and quality assurance ............................................................................ 48
12.1 Data recording................................................................................................................ 48
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 10of 60
12.2 Monitoring ..................................................................................................................... 49
12.3 Data processing .............................................................................................................. 50
12.4 Missing data ................................................................................................................... 50
12.5 Audit and inspection ...................................................................................................... 50
12.6 Archiving ....................................................................................................................... 51
13.Ethical and legal as pects ................................................................................................. 51
13.1 Investigator(s) and other study  personnel ...................................................................... 51
13.2 Funding and financial disclosure ................................................................................... 51
13.3 Ethical and legal conduct of the study ........................................................................... 52
13.4 Patient information and consent..................................................................................... 52
13.5 Publication policy  and use of data ................................................................................. 53
13.6 Compensation for health damage of patients / insurance .............................................. 54
13.7 Confidentiality ............................................................................................................... 54
14.Reference list .................................................................................................................... 54
15.Protocol amendments ...................................................................................................... 55
15.1 Amendment 1 — 26 MAR 2019 .................................................................................... 55
15.1.1 Overview of changes to the study ............................................................................... 55
15.1.2 Modification 1:  Section 10.2.1.1  MRI  equipment .................................................... 56
15.1.3 Modification 2:  Section 10.2.1.2. Pulse Sequences ................................................... 56
15.1.4 Modification 3: Section 10.2.1.2.1  Sequence parameters for brain imaging ............ 5615.1.5 Modification 4: Section 10.2.1.6.1  Quantitative contrast enhancement estimation .. 57
15.1.6 Modification 5:  Section 11.4.2.4   Confidence in diagnosis ...................................... 57
15.1.7 Modification 6:  Section 11.4.2.6  Analy sis of safety  variables................................. 58
16.Appendices ....................................................................................................................... 58
Table of tables
Table 9- 1:  Schedule of Study  Events ...................................................................................... 24
Table 10- 1:  Referral Diagnosis of CNS Lesions ..................................................................... 28
Table 10-2:   Orientation parallel to the planum sphenoidale (onl y for axial) — AMENDED 30
Table 10- 3:  Overview of the imaging efficacy  variables ........................................................ 31
Table of figures
Figure 7 -1:  Structural Formula of Gadobutrol ........................................................................ 20
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 11of 60
List of abbreviations and Definitions of terms
AE adver se event
ADR adverse drug reaction
BBB blood brain barrier
BR blinded reader
BW body weight
CNR contrast to noise ratio
CNS central nervous system
CRA clinical research assistant/associate
CRO clinical research organization
CSF cerebrospinal fluid
DICOM digital images and communications in medicine
GBCA gadolinium -based contrast agent
GCIS General Clinical Imaging Service 
ECCM extracellular contrast medium/media
ECG electrocardiogram
eCRF electronic case report form
EudraCT EU data repository for clinical trials
FAS full analysis set
FDA Food and Drug Administration
FLAIR Fluid Attenuated Inversion Recovery
FSE fast spin echo
GCP Good clinical practice
Gd/Gd3+ gadolinium
GFR glomerular filtration rate 
GMP Good manufacturing practice
HIPAA Health Insurance Portability and Accountability Act 
IB Investigator’s Brochure
ICH International Conference on Harmonization
IEC independent ethics committee
IND Investigational New Drug
Inv investigator
IRB institutional review board
ITF investigator's trial file 
IV intravenous
IVRS  Interactive Voice Response System 
MedDRA Medical Dictionary for Regulatory Activities
MR magnetic resonance
MRI magnetic resonance imaging
NFD Nephrogenic Fibrosing Dermopathy 
nos. numbers
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 12of 60
NSF Nephrogenic Systemic Fibrosis
PID patient identification number
PPS per protocol analysis set
SAE serious adverse event
SDMB study data management book
SH sponsor’s formulation code numbering system
SI signal intensity
TEAE treatment -emergent adverse event
TESAE treatment -emergent serious adverse event
T1 longitudinal relaxation time
T1w T1-weighted
T2 transversal relaxation time
T2w T2-weighted
TMF trial master file
WHODD World Health Organization Drug Dictionary
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 13of 60
3. Introduction
The constant evolution of magnetic resonance (MR) sy stems with faster sequences, functional 
imaging, and multichannel technology  necessitates a contrast agent with the potential to 
benefit from these technical advances. 
Gadobutrol (Gadovist ) was first developed for the indication “contrast enhancement in cranial 
and spinal MRI” in doses of up to 0.3 mmol/kg BW. First approved in Switzerland in 1998, g adobutrol has since been approved in more than 
100countries worldwide (including the Europea n Union countries, USA, Japan, Canada, 
Australia, South Africa, Mexico, New Zealand, Turkey , and several Eastern European and 
Asian countries). Inaddition, g adobutrol has proven to be an effective contrast medium for all 
of its approved indications (CNS, MR angiography, liver and kidney , other body  regions) and 
has exhibited an excellent safety profile, comparable to that of other marketed extracellular 
gadolinium based contrast agents.The ideal extracellular gadolinium-based contrast agent (GBCA )for MR I would have a 
favorable safety  profile and a low risk of potential long -term deposition within normal tissue. 
In this regard, macrocyclic agents GBCA (e.g. gadobutrol, gadoteridol, or gadoterate 
meglumine) that have higher in-vitro and in- vivo stability  and longer dissociation half -lives 
are reasonable alternatives. The standard dose for allmarketed GBCA s, including gadobutrol 
and gadoterate, is 0.1 mmol/kg BWregardless of each agent’s relaxivity .
This study  is designed to examine if a 75 percent dose of gadobutrol (0.075 mmol/kg) , which 
has a high relaxivity ,is noninferior to a 100% dose of gadoterate (Dotarem )(0.1 mmol/kg) for 
steady  state CNS imaging . 
4. Study objectives
4.1 Primary objectives
The pr imary  objective of this study  is to demonstrate noninferiorit y of gadobutrol -enhanced 
CNS imaging (at a dose of 0.075 mmol/kg) compared to gadoterate (0.1 mmol/kg BW) -
enhanced CNS imaging (at a dose of 0.1 mmol/kg) for 3 lesion visualization parameters 
(degree of contrast enhancement, assessment of border delineation, and internal morphology
of lesions ) based on a blinded read.
4.2 Secondary objectives
The secondary  objectives of this study  are to:
Demonstrate noninferiority  for number of lesions based on a blinded read
Confidence in diagnosis
Compare the 0.075 mmol/kg BW dose of gadobutrol to standard dose gadoterate for:
oT1w MRI  image quality  in a paired blinded comparison
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 14of 60
oSensitivity /Specificit y for presence of malignant disease based on a blinded read
Compare the overall contrast enhancement of gadobutrol (0.075 mmol/kg BW) to the 
standard dose of gadoterate (0.1 mmol/kg) for steady -state CNS imaging. Quantitative 
contrast enhanc ement will be performed using an exploratory Overall Contrast 
Enha ncement Estimation Algorithm.
Assess the safet y profile of the reduced dose of 0.075 mmol/kg BW of gadobutrol and 
standard dose gadoterate after intravenous ( IV)admin istration.
5. Study design
5.1 Design overview
This study  is a Phase 4, multicenter, controlled, cross- over stud y with corresponding blinded 
image evaluations in male and female patients at least 18 y ears of age, who are referred for a 
contrast -enhanced MRI of the CNS based on a known or highl y suspected lesion of the CNS . 
Patients will undergo an u nenhanced and contrast -enhanced MRI of the CNS using gadoterate 
at the standard dose of 0.1 mmol/kg BW. If the investigator does not identify  an enhancing 
lesion of the CNS, then this patient will be considered a screening failure. If an enhancing 
lesion i s identified, then the patient will undergo a second unenhanced and contrast- enhanced 
MRI  of the CNS using gadobutrol at a dose of 0.075 mmol/kg BW. 
Safety  will be assessed from the first administration of gadoterate through 24 hours after the 
second adm inistration of gadobutrol .Adverse events will be collected from the signing of 
informed consent through the end of the follow -up period. Serious adverse events (SAEs) will 
be followed through resolution . Patients who receive only  the first MRI  scan (consi dered 
screening failures) will be followed for SAEs only. 
Gadobutrol will be administered at the dose of 0.075 mmol/kg body  weight by  single IV 
injection at a rate of 2 mL/sec, followed b y 20-mL 0.9% saline flush at the same rate. 
Gadoterate will be admin istered at the approved standard dose of 0.1 mmol/kg bod y weight b y 
single IV injection at 2 mL/sec, followed b y 20-mL 0.9% saline flush at the same rate. 
The 2 injections will be separated b y at least 24 hours, but not more than 15 days . 
During the cour se of the study , 2 MRIs will be obtained from each patient as follows:  before 
the administration of each of the contrast agent (unenhanced MRI) consisting of stead y-state 
sequences (T1w, T2w, and FLAIR), following the gadoterate injection ( gadoterate -enhanced 
MRI ) consisting of steady -state sequences T1; and following the gadobutrol injection 
(gadobutrol -enhanced MRI ) consisting of steady -state sequences (T1w).
The unenhanced MR image set, combined unenhanced and gadobutrol- enhanced MR image 
sets, and the unenhanced and combined unenhanced and gadoterate -enhanced MR image sets 
will be evaluated b y 3 independent blinded readers . The blinded readers will also evaluate the 
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 15of 60
gadobutrol -enhanced T1w images compared to the gadoterate-enhanced T1w images in a 
paired read for image quality . 
The final clinical diagnosis will be determined b y the site investigator using all available 
clinical information up to 30 day s post the first MRI .This final clinical diagnosis will be 
utilized as the standard of truth for the blinded assessment of diagnostic performance 
(sensitivity /specificit y for malignant disease).
The safet y of the patients will be assessed b y monitoring of adverse events and treatment 
emergent adverse events (TEAEs) . 
5.2 Primary variable(s)
The 3 primary  efficacy  variables will be lesion visualization parameters based on a blinded 
read (see Section 10.2.1.5 for details):  
Degree of lesion contrast enhancement
Lesio n border delineation
Lesion internal morphology
5.3 Secondary efficacy variables
The secondary  efficacy  variables are the :
Number of lesions identified (up to 10) based on a blinded r ead
Identification of b enign or m alignant disease based on blinded read
Confidence in diagnosis based on a blinded read
Image qualit y based on a blinded read
Contrast enhancement utilizing an exploratory  Overall Contrast Enhancement 
Estimation Algorithm.
5.4 Justification of the design
Gadoterate is an approved macrocy clic contra st agent for steady -state CNS imaging . Ithas the 
lowest relaxivity  among all approved gadolinium contrast agents and was therefore chosen as 
the comparator . Gadoterate belongs to the same chemical class as gadobutrol, which is also a 
macrocy clic contrast agent . Macrocyclic contrast agents may  be considered preferable to 
linear agents in ce rtain situations, for example, in light of Nephrogenic S ystemic Fibrosis 
(NSF), which has been rarely  observed in renall y impaired patients who received multiple 
and/or high doses of primarily  linear GBCAs, and in the accumulation of gadolinium in 
tissues, also thought to occur to a lesser extent with macrocyclic agents. In addition, as both 
of these conditions appear to be dose-related, the lowest dose of gadolinium is r ecommended. 
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 16of 60
The purpose of this stud y is to demonstrate that the higher relaxivity  of gadobutrol compared 
to gadoterate will permit a dose reduction by  25% for gadobutrol and still provide noninferior 
efficac y to a full dose of gadoterate.
The patient pop ulation for this study  will be those with known or highl y suspected lesions of 
the CNS referred for a contrast- enhanced MRI of the CNS.
The multicenter design is used to gain a wide range of experience and to reduce bias . 
A prospective planned blinded image evaluation by  independent readers will be performed in 
order to facilitate an independent evaluation and permit randomization of the image 
evaluation . The blinded readers will be experienced radiologists who will not have been 
involved in the clinica l portion of the study  and are considered independent from the study . 
Selecting experienced readers and performing adequate and extensive reader training prior to the evaluation of the images is expected to sufficiently address standardization issues and t o 
minimize inter -reader variability . All quantitative measurements and qualitative evaluations of 
the MRI  data will be performed in a core laboratory  in a standardized fashion using validated 
software . 
5.5 End of study
The end of the patients’ participation in the study  will be reached at the last patient last visit, 
defined as when the final clinical diagnosis is obtained for the last patient enrolled . The end of 
the study  will be considered the end of the blinded read, approximately 30 days after the 
LPLV . 
5.6 Primary objectives
The primary  objective of this study  is to demonstrate noninferiorit y of gadobutrol -enhanced 
CNS imaging (at a three -quarter dose of 0.075 mmol/kg) compared to gadoterate - enhanced 
CNS imaging (at a full dose of 0.1 mmol/kg) for 3lesion visualization parameters (degree of 
enhancement, border delineation, internal morphology ) based on a blinded read.
5.7 Primary completion
The primary  completion event for this study  is completion of the blinded read for all patients.
The primary  completion date for this study  according to the FDA Amendment Act is specified 
in a separate document (not part of this study  protocol).
6. Study population
6.1 Eligibility
Male and female patients ( ≥ 18 y ears of age) of any  ethnic group, who meet the inclusion 
criteria and none of the exclusion criteria, and who give written informed consent will be eligible for enrollment into the study .
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 17of 60
6.2 Inclusion criteria
To be included in the study  apatient must :
1.Have known or hig hly suspected CNS pathology referred forcontrast -enhanced MRI of 
the CNS based on current clinical sy mptoms or on a previous procedure.
2.Iffemale and of child bearing potential , have a negative urine pregnancy  test within 
1hour prior to the administration of gadoterate (the first MRI).
3. H avean estimated glomerular filtration rate (eGFR) value ≥ 60 mL /min/1.73m2derived 
from a serum creatinine result within four (4) weeks prior to the first study  MRI .
4.Befully informed about the study , including pro visions of the Health Insurance Portability  
and Accountability  Act (HI PAA) as applicable, and consent to participate
6.3 Exclusion criteria
Apatient will be excluded from the study  if he/she:
1.Has n o enhancing lesion visible on the gadoterate -enhanced MRI scan.
2.Is pregnant or breast feeding
3.Has received an y investigational product or has participated in an y other clinical trial 
within 30 day s prior to enrolling in this study
4.Has an y contraindication to the MRI examinations or the use of gadolinium -containing 
contras t agents
5.Has a history  of severe allergic or anaphy lactic /anaphy lactoid reaction to any  allergen 
including drugs and contrast agents
6.Has received an y gadolinium -based contrast agent <24 hours prior to the study  MRIs, or 
is scheduled to receive any contrast agent within 24 hours after the second study  MRI
7.Is considered clinicall y unstable
8.Has severe cardiovascular disease (eg, known long QT s yndrome, acute myocardial 
infarction [< 14 day s], unstable angina, congestive heart failure New York Heart 
Association class IV or acute stroke (< 48 hours) 
9. Is expected or is scheduled to have a change in any  treatment or procedure between the 
gadoterate and gadobutrol MRI s that may  alter image comparability
10.Is scheduled or is likel y to require a biopsy  or any  interventional therapeutic procedure 
from the first study  MRI up to 24 hours after the second study  MRI
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 18of 60
6.4 Justification of selection criteria
The following is the FDA class warning for gadolinium- based contrast agents:
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium -based contrast agents increase the risk for Nephrogenic Systemic Fibrosis (NSF) in patients with:
acute or chronic severe renal insufficiency (glomerular filtration rate < 30mL/min/1.73m2), or acute renal 
insufficiency of any severity due to h epato -renal syndrome or in the perioperative liver transplantation period.
In these patients, avoid use of gadolinium -based contrast agents unless the diagnostic information is essential and 
not available with non -contrast -enhanced MRI . NSF may result in f atal or debilitating systemic fibrosis affecting 
the skin, muscle and internal organs . Screen all patients for renal dysfunction by obtaining a history and/or 
laboratory tests . 
When administering a gadolinium -based contrast agent, do not exceed the recom mended dose and allow  a 
sufficient period of time for elimination of the a gent from the body prior to any readm inistration.
It must be ensured that each patient is suitable for the technical requirements of a MRI  
examination, and especially  that each patient has no metallic implants that would be affected 
by magnetic fields ( Exclusion criterion 4) . 
In order to prevent interference with the investigational product and to ensure that the cause 
ofTEAEs can be easily  traced, no other contrast agents are to be administered ( Exclusion 
criteria 6and 7). 
The phy sical condition of each patient must be stable and must not be significantly  influenced 
by other therapies so that the patient does not have the potential for demonstrating unrelated
TEAEs after cont rast agent administration ( Exclusion criterion 6 ). 
To ensure that the patient’s clinical picture is the same during gadobutrol -enhanced MRI and 
the gadoterate -enhanced MRI  and there is no change due to external influences, no local or 
systemic therapy  or biopsy /interventional therapeutic procedure should occur between the 
2MRI  examinations (Exclusion criteria 10 and 11). 
6.5 Recruitment
Patient recruitment will be from the patient populations at the investigative study  centers who 
are referred for a contrast -enhanced CNS MRI . 
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 19of 60
6.6 Withdrawal of patient s from study
6.6.1 Withdrawal
Withdrawal criteria
Patients must be withdrawn from the stud y if an y of the following occurs:
At their own request or at the request of their legally  acceptable representative. At any  
time during the stud y and without giving reasons, a patient may decline to participate 
further . The patient will not suffer an y disadvantage as a result.
Patients may be withdrawn from the stud y if an y of the following occurs:
If, in the investigator's opinion, continuation of the study  would be harmful to the 
patient's well -being
At the specific request of the sponsor and in liaison with the investigator (e.g. obvious
non-compliance, safet y concerns).
Depending on the time point of withdrawal, a withdrawn patient is referred to as either 
“screening failure” or “dropout” as specified in the following:
Screening failure
A patient who for an y reason (e.g. failure to satisfy  the inclusion/exclusion criteria), 
terminates the study  before the time point used for the definition of “dropout” (see below) is 
regarded a “screening failure” . 
DropoutA patient who satisfies all eligibility  criteria, and discontinues study  participa tion prior to the 
second MRI not due to an adverse event is defined as a “dropout” if the patient has alread y 
been submitted to the first study  MRI .
General proceduresIn all cases, the reason for withdrawal must be recorded in the CRF and in the patient 's 
medical records. 
The patient may object to the generation and processing of post- withdrawal data as specified 
in Section 13.4.
Any patient removed from the trial will remain under medical supervision until discharge or 
transfer is medically  acceptable.
Details for the premature termination of the study  as a whole (o r components thereof) are 
provided in Section 13.
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 20of 60
6.6.2 Replacement
Patients who have undergone a gadoterate -enhanced MRI  but have no enhancing lesions 
identified will not be enrolled. Recruitment will, therefore, continue until at least 180 patients 
have completed both the gadoterate and gadobutrol studies.
6.7 Patient identification
The patient number is a 9 -digit number consisting of:
Digits 1 to 5= Unique center number
Digits 6 to 9 = Current patient number within the center
After patients have signed an informed consent form, they  will be identified by  a unique 
9digit patient identification number (PID) . The PID will identify  the patient throughout the 
study . The first 2 dig its represent the country  number, the second 3 digits represent the center 
number, and the third 4 digits represent a sequential number in the order in which the patient 
signed the informed consent at the study  center . For example, the third patient enrolled 
at center number  in the  (14) would be PI D 
7. Treatments
7.1 Treatments to be administered
7.1.1 Gadobutrol
Gadobutrol injection (Gadovist /Gadavist ) is the gadolinium complex of 10 -[2,3-dihydroxy -1-
(hydroxy methy l) propy l]-1,4,7,10- tetraazacy clododecane -1,4,7- triacetate (see Figure 7-1). 
This is a neutral chelated, r acemic complex of the rare earth element gadolinium (Gd3+). 
Gadobutrol injection is a white to off- white, highly  water soluble substance that is an 
injectable contrast medium for MRI . Gadobutrol is to be administered by  IV injection. 
Figure 7-1:  Structural Formula of Gadobutrol
Molecular weight:  604.72 g/molNN N
N
OHOH HH
OHGdO- -O
-OO O
O3+
(Racemate)
PPD
PPD
PPD
PPD
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 21of 60
Each milliliter of 1.0 molar gadobutrol injection (SH L  562 BB) contains 604.72 mg of pure 
gadobutrol, 0.513 mg calcium sodium butrol, 1.211 mg trom ethamine, 0.1N hy drochloric acid 
and water for injection . Gadobutrol injection contains no antimicrobial preservative . For a 
description of the product characteristics, including pertinent phy sicochemical data, see the 
Investigator’s Brochure . 
7.1.2 Gadoterate treatment
The comparator contrast agent is gadoterate ( Dotarem ®/Clariscan™), which is approved for 
steady -state CNS imaging . (See www.guerbet.com for Dotarem package insert , GE 
Healthcare for Clariscan .)
7.2 Dosage and administration
Patients will receive a single dose of gadoterate at the approved dose, 0.1 mmol/kg BW
(±10percent) , via IV bolus administration using a power injector via a peripheral vein (the 
antecubital vein is preferred) . Gadoterate will be injected at a rate of 2 mL/second followed b y 
a 20-mL 0.9% saline flush at the same rate. If the patient is eligible for inclusion in the study , 
the patient will undergo a second contrast- enhanced MRI  using a single dose of gadobutrol 
0.075 mmol/kg BW via IV bolus administration using a power injector v ia a peripheral vein 
(the antecubital vein is preferred) . Gadobutrol will be injected at a rate of 2 mL/second 
followed b y a 20 -mL 0.9% saline flush at the same rate. 
The administration of gadoterate and gadobutrol is not randomized. During the 24 -hour 
follow-up period after the gadoterate injection and during the 24-hour follow -up period after 
the gadobutrol injection, no other contrast agent should be given . 
7.3 Identity of study treatment
Marketed drugs will be used for this study . If required at country  level, the study  drugs will be 
labeled according to the requirements of local law and legislation . Label text will be approved 
according to the sponsor’s agreed procedures, and a copy  of the labels will be made available 
to the study  site upon request.
Acomplete record of batch numbers and expiry  dates of all study  treatment as well as the 
labels will be maintained in the sponsor’s study  file.
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 22of 60
7.4 Blinding
The study  is formally  unblinded, however, all primary  and most secondary  efficacy  endpoints 
(except for th e open -label site investigator assessments) are blinded . 
For the off -site blinded read, study  images for each subject will be reviewed both unpaired 
andpaired . The gadoterate and gadobutrol image sets from the same patient will be 
randomized. For the paired reading, the gadoterate and gadobutrol images will be show n
randomly  on either the right or left monitor .   
Three experienced radiologists who are not involved with the conduct of the study , the 
evaluation of local stud y images at the site, and/or the recruitment of patients will be selected 
to perform the independent blinded image evaluations . Each blinded reading session will have 
sufficient separation (at least 2 weeks) between the unenhanced and combined unenhanced 
and enhanced MRI for each contrast agent to minimize recall bias (see Section 11.4). The 
images used for blinded evaluation sessions will not contain an y information regarding the 
patient’s privacy  or clinical data . Information on study  center, scanner manufacturer, or 
imaging times willnot be provided to the blinded reviewers . 
7.5 Drug logistics and accountability
The investigator will use the study  drug onl y within the framework of this clinical study  and 
in accordance with this study  protocol . A record of the volume received will be recorded in 
the patients’ eCRFs . Receipt and return of the study  drugs must be properly  documented on 
the forms provided b y the sponsor.
7.6 Treatment compliance
The stud y drugs are administered b y study center personnel who will record:
Location of injection  
Study  drug start date and time
Study  drug volume and rate of injection  
The injection volume and rate of injection of the saline flush will be recorded in the eCRF .
8. Non-study therapy
8.1 Prior and concomitant therapy
Patients are not to receive an y contrast agent within 24 hours prior to the first study  MRI or 
24hours after the second study  MRI . Patients may receive other concomitant medications, 
including sedation for the MRI  examination, during the study . A patient’s current medication 
regimen and/or an y additional medication taken from baseline up to 24 hours after the second 
study  MRI will be recorded in the eCRF . 
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0   Page: 23of 60
8.2 Post-study therapy
Not applicable as this is a diagnostic -imaging study .
9. Procedures and variables
9.1 Tabular schedule of evaluations
Table 9-1 display s the schedule of evaluations and procedures for the study .
Clinical Study  Protocol
No. BAY No. 86-4875 / IMPACT no.19773   
26 MAR 2019    Version no. 2.0 Page: 24of 60
Table 9-1:  Schedule of Study Events
Study Period 1aStudy Period 2a
Final Diagnosis 
up to 30 day s 
Phone callEvaluation/Procedure
Baselineb MRIPost 
Injection
Phone 
ContactcBaselinec MRIPost 
Injection
Phone 
Contactc
TimePointUp to 72 hours 
prior to the 
1st MRIUnenhanced Enhanced 24h±4hWithin
24h
ofthe 
2ndMRIUnenhanced Enhanced24h 
(±4h)
Sign informed consent X
Dem ographic data X
Medical/surgical history X
Baseline findings X
Referral diagnosis X
Previous/concomitant
medicationsdX X X X
WeighteXiXi
Urine pregnancy testfXi
Creatinine valueg X
Gadoterate administration X
Gadobutrol administration X
Adverse event monitoring X X X X X X X X
Final clinical diagnosis up to 
30 day  post first MRIh X
Clinical S tudy Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019 Version no. 2.0  Page: 25of 60
Abbreviations: h = hour(s); immed = immediately; inj = injection; min = minutes
Notes;
aA period of 24 h up to 15 days is requ ired between the contrast agent injections;
bBaseline for study period 1 is from a fter signing informed consent up to 72 hours for gadoterate administration ; 
cBaseline for study period 2 is within the 24 h prior to administration of gadobutrol. At least 2 h is required between the 24 -h follow -up evaluations from study period 1 and the baseline 
evaluations for study period 2. The patient will be contacted by phone after 24 -hour (± 4 hours) after each contrast agent injection . The two MRI contrast agents will be separated by at least 
24hours, but not more than 15 days . Any TEAEs or TESAEs and/or concomitant medi cations reported during this period will be recorded in the eCRF.
dAll c oncomitant medication will be collected 
eWeight will be obtained at baseline and reconfirmed prior to the second MRI
fUrine pregnancy test (if applicable) to be done at the site, according to the standard of the institution, and the results must be available prior to the gadoterate MRI.
gSerum creatinine (eGFR value calculated using either MDRD or the CKD-EP I Creatinine Equation , 2009) derived up to 4 weeks prior to the first study MRI value and date obtained and 
method used needs to be recorded at Screening .
hThe final clinical diagnosis will be recorded by the in vestigator within 30 days of the first study MRI. 
i Within 1h of injection
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019                                                        Version no. 2.0                                      Page: 26of 60
9.2 Study periods
9.2.1 Baseline study period 1
Baseline is the up to 72 hour period from signing informed consent to administration of 
gadoterate (including saline flush). 
Prior to administration of gadoterate the followi ng will be performed: placement of IV injection 
line, urine pregnancy  test (in wome n of child bearing potential the date and time of the pregnancy  
test sample and the result of the pregnancy  test wi ll be recorde d in the eCRF ). Results of the 
pregnancy  test must be negative prior to the administration of any  contrast agent.
The IV injection line will consist of a large bore indwelling catheter (at least 18 gauge) preferably
placed in an antecubital vein . The location of the IV injection line must be documented in the 
eCRF . 
9.2.2 Study period 1
The administration of gadoterate is study  period 1 and the administration of the gadobutrol is 
study  period 2. 
The following procedures will be performed during s tudy period 1:
1. An unenhanced MRI of the brain will be performed according to the standards of the 
institution . 
2.The appropriate volume corresponding to 0.1 mmol/kg of gadoterate will be administered 
IVas a bolus injection at the rate of 2 mL/sec using a power inje ctor via a peripheral vein 
(the antecubital vein is preferred) followed b y a 20 -mL 0.9% saline flush using a power 
injector at the same flow rate. The dose and volume of the contrast agent will be recorded . 
3.AE monitoring will begin at baseline . All TEAEs will be monitored for 24 hours after the 
administration of each contrast agent. However, if no enhancing lesion is identified in the first 
imaging study , the patient will not be included in the safet y database and only  SAEs for that 
patient would be reported. 
4.Conventional steady -state contrast-enhanced imaging with a T1w sequence according to 
theparameters listed in Section 10.2.1.2 will start 4 to 10 minutes following the injection of 
the contrast agent. 
5.The patient will be asked about his/her phy sical condition . Any  clinicall y significant changes 
in the patient's ph ysical condition from the baseline values are to be recorded in the eCRF, 
and the TEAE section is to be completed accordingly. 
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019                                                        Version no. 2.0                                      Page: 27of 60
According to the internal clock of the MR device, the date and start time of the first MR 
sequence, date and start time of the contrast injection and the end time of the complete MR examination will be recorded in the eCRF . Any deviation from the specified MRI procedures and 
the reason for it (scanner -related problem or patient- related problem) will be recorded in the 
eCRF . 
9.2.3 Baseline study period 2
Any changes in concomitant diseases and concomi tant medication will be recorded in the eCRF . 
The IV injection line will consist of a large bore indwelling catheter (at least 18 gauge) preferabl y 
placed in an antecubital vein. The location of the IV injection line must be documented in the 
eCRF . 
9.2.4 Study period 2
The following procedures will be performed:
1.An unenhanced MRI will be performed exactl y as done in Study  Period 1. 
2. The appropriate volume of 75% of the standard gadobutrol dose (0.075 mmol/kg BW) will be 
administered IV as a bolus injection at the rate of 2 mL/sec using a power injector via a 
peripheral vein (the antecubital vein is preferred) followed by  a 20 -mL 0.9% saline flush 
using a power injector at the same flow rate. The dose and volume of the contrast agent will be recorded. 
3.Conventio nal steady -state contrast-enhanced imaging with a T1w sequence according to the 
parameters listed in Section 10.2.1.2 will start 4 to 10 minutes following the injection of the contrast agent.
4.The patient will be asked about his/her phy sical condition . Any  clinicall y significant changes 
in the patient's ph ysical condition from the baseline values are to be recorded in the eCRF, 
and the TEAE section is to be completed accordingl y.
The date and start time of the first MR sequence, date and start time of the co ntrast injection and 
the end time of the complete MR examination will be recorded in the eCRF . Any deviation from 
the specified MRI procedures and the reason for it (scanner -related problem or patient-related 
problem) will be recorded in the eCRF. 
9.2.5 Post-Injection phone contact
The patient must be contacted b y phone after 24-hour (± 4 hours) after each contrast injection . 
The two MRI  contrast agents will be separated by  at least 24 hours, but not more than 15 day s. 
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019                                                        Version no. 2.0                                      Page: 28of 60
Any TEAEs or TESAEs and/or concomitant medi cations reported during this period will be 
recorded in the eCRF. 
The end of Stud y Period 2 is after the 24 hour post injection AE follow- up phone call.
9.2.6 Final clinical diagnosis
The final clinical diagnosis and whether this represents malignant disease will be determined by  
the investigator using all available clinical information available up to 30 day s post-first MRI. 
10.Procedures and variables
10.1 Population characteristics
Male and female patients of any ethnic group, who meet the inclusion criteria and n one of the 
exclusion criteria, will be eligible for enrollment into the study .
10.1.1 Demographic
Demographic data ( yearof birth, age, sex, ethnic group), height, weight, baseline findings, and 
the suspected or known referral diagnosis according to Table 10-1 will be obtained at baseline.
Table 10-1:  Referral Diagnosis of CNS Lesions
Meningioma 
Anaplastic/maligna nt meningioma
Glial tumor, low grade (I/II)
Glial tumor , high grade (III/IV)
Glial tumor, tumor grade cannot be determined 
Metastases
Multiple sclerosis (acute and chronic)
Optic neuritis
Meningeal disease (focal enhancement)
Pituitary adenomas (macro and micro)
Craniopharyngiomas
Tumors of the ch oroidal plexus
Tumors of the pineal gland
Meningeal carcinomatosis
Oligodendrogliomas grade II
Oligodendrogliomas grade III 
(anaplastic/malignant)Chordomas
Primary lymphoma
Dermoid/Epidermoid tumors
Infectious di sease (eg, brain abscess, cisticercosis, etc)
Venous angiomas
Meningeal spread of meningiomas (dural involvement)
Cerebelopontine angle tumors
Von Hippel Lindau syndrome
Hypertensive leukoencephalopathy
Subacute/chronic ischemia
Encephalitis
Others, specify
Not assessable
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019                                                        Version no. 2.0                                      Page: 29of 60
10.1.2 Medical history
Medical history  findings (i.e. previous diagnoses, diseases or surgeries) meeting all criteria listed 
below will be collected as available to the investigator:
Start before signing of the informed consent 
Considered relevant for the patient ’s study  eligibility .
Detailed instructions on the differentiation between (i) medical history  and (ii) adverse events can 
be found in Section 10.4.1.1.
10.1.3 Prior and concomitant medications
Any medication received within 72 hours prior to the first contrast agent through 24 hours after 
the second contrast agent will be recorded in the eCRF ,including the drug name (brand name is 
preferred), indication, total daily dose, route of administration, and start and stop dates. Any  
changes in concomitant medication will also be recorded . 
No contrast agent is allowed to be administered within 24 hours prior to the study  MRIs or during 
the study  period.
10.2 Efficacy
10.2.1 MRI procedures
10.2.1.1 MRI equipment —AMENDED
The procedure will be performed using either a 1.5 or a 3.0 Tesla MRI scanner that can perform 
the required pulse sequences (see Section 10.2.1.2) with a dedicated head coil. The manufacturer, 
model, software version, and field strength of the MRI  device will be recorded in the eCRF. The 
same scanne r and required pulse sequences must be used for both the gadoterate and gadobutrol 
enhanced MRI’s.
The same field strength (either 1.5 or 3.0) must be used for both scans . Mixed field strength scans 
are not permitted. In addition, T1w enhanced sequences must be performed at or near the same post -dose timepoint 
(4-10 mins) for each study  drug (gadoterate and gadobutrol) .
10.2.1.2 Pulse sequences —AMENDED
The same parameter setting must be used for unenhanced T1w images and for contrast -enhanced 
T1w images in each patient. T1w s pin echo/FSE acquisition should be performed in 2D mode.
The required pulse sequences for gadobutrol and gadoterate are:  
Unenhanced (axial and sagittal image presentation for brain)
oT1w spin- echo /FSE images of the whole brain -axial
oFluid Attenuated Inversion Recovery  (FLAI R) of the whole brain –axial
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019                                                        Version no. 2.0                                      Page: 30of 60
oOptional: T2w spin- echo images of the whole brain – sagittal or axial
Contrast -enhanced (axial and coronal image presentation for brain)
oT1w spin echo/ FSE images of the whole brain
General considerations
oThe MR scanner should NOT be actively  retuned after the unenhanced sequences  
Deviations from the specified MRI  procedure will be recorded in the eCRF . 
10.2.1.2.1 Sequence parameters for brain imaging —AMENDED
The recommended sequen ce parameters for brain imaging i s display ed below in Table 10-2.
Table 10-2:   Orientation parallel to the planum sphenoidale (only for axial) —AMENDED
T2 SE/FSE T1 FLAIR
Plane Sagittal or Axial Axial or Coronal Axial
Pulse Sequence Spin echo /FSE Spin echo /FSE IR
Patient position Supine Supine Supine
Coil Head Head Head
Slice thick/spacing 3-5skip 0-1.5 3-5skip 0-1.5 3-5 skip 0-1.5
Frequenc y ≥256 ≥256 ≥256
Phase ≥256 ≥256 ≥128
Nex ≥2 ≥2 ≥1
10.2.1.3 Quality assurance of images
The investigator must assure that the unenhanced MRI  image set (T1w, FLAI R and T2w) is of 
acceptable diagnostic quality . It is known that in CNS imaging, motion artifacts, aliasing artifacts, 
and/or other disturbing artifacts (e.g. metal implants or dental brace) can, in rare instances impact 
the ability  to interpret images of the brain .In such cases, the enhanced images will also be 
similarly  impacted. The investigator must insure that the unenhanced images are interpretable, or 
document wh y the technical quality  impacts the evaluation . 
All image sets will be sent to the imaging core lab ( the Bay er internal G eneral Clinical Imaging 
Service, GCIS) . 
Quality  control and quality  assurance of the MR images and conduct of the blinded readings will 
be done at the image core laboratory , GCIS in Berlin, Germany .
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773
26 MAR 2019                                                        Version no. 2.0                                      Page: 31of 60
10.2.1.4 Image archiving and copying
Once all the stud y-related images are acquired, both sets of unenhanced images and all contrast-
enhanced MRI images must be stored on appropriate archival media at the site. St udy images 
should be uploaded to GCI S without time delay  (max. 5 business day s). 
The images must not include the patient’s privacy  data such as name or initials or other personal 
identifier, sex and birth date, but his/her patient number and the stud y num ber must be included. 
No further information needs to be given. Further details and guidance for the sites will be 
provided in the Imaging Manual b y GC IS. An overview of the imaging efficacy  variables is 
provided in Table 10-3. 
Table 10-3:   Overview of the imaging efficacy variables
Unenhanced
MRI 1Combined 
unenhanced 
and gadoterate-
enhanced MRUnenhanced
MRI 2Combined 
unenhanced 
and gadobutrol -
enhanced MRIPaired 
Gadobutrol-
enhanced T1w 
and Gadoterate -
enhanced T1w 
MRI
Variables BR BR BR BR BR
Degree of contrast 
enhancement (lesions)   
Assessment of border 
delineation (lesions)   
Internal morphology 
(lesions)   
Overall contrast 
enhancement (Core Lab)   
Total number of lesions 
detected    
Malignant Disease  
Confidence in diagnosis  
Image quality 
10.2.1.5 Primary efficacy variables
The following 3 lesion visualization parameters scored by  the blinded readers constitute the 
primary  efficacy  variables:  
Degree of lesion contrast enhancement
Lesion Border delineation
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 32of 60
Lesion Internal morphology
The i ndependent blinded readers will evaluate the 3primary  variables (visualization parameters) 
for up to the 5 largest lesions in each of the following images/image sets separatel y:  
Unenhanced and Combined unenhanced (T1w, T2w, FLAIR) and gadoterate -
enhanced (T1w) MR image sets
Unenhanced and Combined unenhanced (T1w, T2w, FLAIR) and gadobutrol -
enhanced (T1w) MR image sets
For the evaluation of the degree of contrast enhancement, border delinea tion, and internal 
morphology  the blinded readers will score the lesion using the image sequence which best depicts 
each variable.
10.2.1.5.1 Degree of contrast enhancement
A total of up to the 5 largest lesions will be selected and scored b y the blinded readers.
Thefollowing 4 -point scale will be used for lesion enhancement:  
1 = No lesion is not enhanced 
2 = Moderate lesion is weakly  enhanced
3 = Good lesion is clearl y enhanced
4 = Excellent lesion is clearl y and brightly enhanced
The score for each lesion will b e recorded in the eCRF. This will be evaluated according to Table
10-3. 
10.2.1.5.2 Border delineation
Up to 5 of the largest lesions will be selected and scored by the blinded readers.
The following 4 -point scale will be used for lesion delineation:  
1 = None no or unclear delineation of the lesion boundaries
2 = Moderate some aspects of border delineation covered
3 = Good almost clear, but not complete delineation
4 = Excellent clear and complete delineation
The internal morphology score will be recorded into eCRF . This will be evaluated according to 
Table 10-3.
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 33of 60
10.2.1.5.3 Internal morphology
Up to 5 of the largest lesions will be selected and scored b y the blinded readers.
The following 3 -point scale will be used for lesions:
1 = Poor the structure and internal morphology  of the lesion is poorly  visible
2 = Moderate the structure and internal morphology  of the lesion is partially  visible   
3 = Good the structure and internal morphology  of the lesion is sufficiently  
visible  
The internal morphology score will be recorded into eCRF . This will be evaluated acc ording to 
Table 10-3.
10.2.1.6 Secondary efficacy variables
10.2.1.6.1 Quantitative contrast enhancement estimation -AMENDED
Quantitative contrast enhancement estim ation will be performed using a n exploratory Overall 
Contrast Enhancement Estimation Algorithm. Descriptive statistics will be presented for each 
study  drug (gadoterate and gadobutrol) . 
10.2.1.6.2 Diagnosis of Malignancy /Confidence in Diagnosis
The blinded readers will determine if the pathology  detected in the combined image sets isbenign 
or malignant . These scores will be matched with the final diagnosis of malignant or benign 
disease based on the final diagnosis provided b y the Investigator.
The blinded reader s will record in the eCRF his/her confidence in diagnosis for each patient for 
the combined unenhanced and gadobutrol -enhanced MR image sets, and the combined 
unenhanced and gadoterate- enhanced MR image sets separately . 
Diagnostic confidence will be evaluated to determine the level of certaint y that the blinded 
readers assign to a diagnosis. This is defined as the degree of confidence that the information on 
the images represents the true and complete clinical picture of a patient . The degree of confi dence 
will be rated on a 4 -point scale:  
1 = Not confident
2 = Some what confident
3 = Confident4 = Very  confident
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 34of 60
10.2.1.6.3 Image quality
The blinded readers will evaluate the relative image quality  of the gadobutrol -enhanced T1w MR 
images and the gadoterate- enha nced T1w MR images. The assessment will be based on the 
overall subjective interpretation of the degree of contrast enhancement, border delineation, and 
internal morphology . These images will be presented in a paired fashion in a separate reading 
session. The gadobutrol and gadoterate images will be randomly assigned to either the left (image L) or right (image R) positions.
Image qualit y will be compared on a 5 -point scale:  
1 = Image R is worse
2 = Image R is slightl y worse
3 = Image R is same
4 = Image R is slightl y better
5 = Image R is better
10.2.1.6.4 Total number of lesions
For each image set, the blinded reader is to record the total number of lesions up to a maximum 
of10 lesions.
10.3 Pharmacokinetics
Not applicable.
10.4 Safety
10.4.1 Adverse events
10.4.1.1 Definitions
Definition of adverse event ( AE) and treatment emergent AE s
In this stud y, adverse events (AEs), defined as any untoward medical occurrence (i.e. any 
unfavorable and unintended sign [including abnormal laboratory  findings], sy mptom or disease) 
in a patient or clinical investigation patient after signing informed consent will be recorded. 
A treatment emergent AE is defined as an y AE that is reported after the patient has received at 
least one dose of stud y drug . Therefore, a TEAE may  or may  not be temporally  or causall y 
associated with the use of a medicinal (investigational) product.
Pathology  identified on the MRI  will not be considered a TEAE. 
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 35of 60
A surgical procedure that was planned prior to the start of the study  by any physician treating the 
patientshould not be recorded as a TEAE (however, the condition for which t he surgery  is 
required may  be a TEAE).
In the following differentiation between medical history  and TE AEs, the term “condition” may  
include abnormal e.g. physical examination findings , symptoms, diseases, laboratory results, 
ECG.
Conditions that started before signing of informed consent and for which no sy mptoms or 
treatment are present until signing of informed consent are recorded as medical history
(e.g. seasonal allergy  without ac ute complaints).
Conditions that started before signing of informed consent and for which symptoms or 
treatment are present after signing of informed consent, at unchanged intensity , are 
recorded as medical history (e.g. allergic pollinosis) .
Conditions that started or deteriorated after signing of informed consent will be 
documented as adverse events. This includes intercurrent illnesses.
Definition of serious AE (SAE) and treatment emergent serious ( TESAE)
A SAE is classified as any untoward medical occur rence that, at any dose, meets an y of the 
following criteria (a –f)and a TESAE is an y SAE that is reported after the patient has received at 
least one dose of stud y drug . 
The criteria for both an SAE and a TESAE are:
a.Results in death
b.Is life -threatening
The term ‘life -threatening’ in the definition refers to an event in which the patient was at 
risk of death at the time of the event, it does not refer to an event which h ypothetically  
might have caused death if it were more severe.
c.Requires inpatient hosp italization or prolongation of existing hospitalization
A hospitalization or prolongation of hospitaliz ation will not be regarded as a SAE or 
TESAE if at least one of the following exceptions is met:
-The admission results in a hospital stay  of less than 12hours
- The admission is pre- planned
(e.g. elective or scheduled surgery  arranged prior to the start of the study ; admission is 
part of the stud y procedures as described in Section 9.2)
-The admission is not associated with an AE 
(e.g. social hospitalization for purposes of respite care).
However, it should be noted that invasive treatment during an y hospitalization may fulfill 
the criterion of ‘me dically  important’ and as such may  be reportable as a SAE / TESAE 
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 36of 60
dependent on clinical judgment . In addition, where local regulatory  authorities 
specificall y require a more stringent definition, the local regulation takes precedence.
d.Results in persistent or significant disability  / incapacity
Disability means a substantial disruption of a person’s ability  to conduct normal life’s 
functions.
e.Is a congenital anomal y / birth defect
f.Is another serious or important medical event as judged b y the investigator
10.4.1.2 Classifications for adverse event assessment
AllAEs / TEAEs will be assessed and documented by  the investigator according to the categories 
detailed below . 
10.4.1.2.1   Seriousness
For each AE / TEAE, the seriousness must be determined according to the criteria given in 
Section 10.4.1.1.
10.4.1.2.2 Intensity
The intensity  of an AE / TEAE isclassified according to the following categories:
-Mild
-Moderate
-Severe
10.4.1.2.3 Causal relationship 
The assessment of the causal relationship between an AE / TEAE andthe administration of 
treatment is a decision to be made by the investigator, who is a qualified physician, based on all 
information available at the time of the completion of the CRF.
Causality  should be assessed separately for each study treatment as detailed in the CRF . If the 
investigator feels that the event cannot be firml y attributed to one of the study treatments 
(e.g. owing to a suspected underlying interaction), the s ame assessment will be documented for 
each stud y treatment.
The assessment is based on the question whether there was a “reasonable causal relationship” to the study  treatment in question.
Possible answers are “y es” or “no”
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 37of 60
An assessment of “no” would incl ude:
1.The existence of a high lylikely  alternative explanation, e.g. mechanical bleeding at 
surgical site.
or
2.Non-plausibility , e.g. the patient is struck by  an automobile when there is no indication 
that the drug caused disorientation that may have caused the event; cancer developing a 
few day s after the first drug administration.
An assessment of “y es” indicates that that the TEAE is reasonabl y associated with the use of the 
study  treatment.
10.4.1.2.4 Other specific treatment(s) of AEs / TEAEs
-None
-Remedial drug the rapy
-Other
10.4.1.2.5 Outcome
The outcome of the AEs / TEA Esis to be documented as follows: 
-Recovered/resolved
- Recovering/resolving
-Recovered/resolved with sequelae
-Not recovered/not resolved
-Fatal
-Unknown
10.4.1.3 Assessments and documentation of adverse events
The investigator must record on the respective CRF pages all adverse events occurring in the 
period between the signing of the informed consent and the end of the follow -up phase; all 
SAEs/TESAEs must be followed to resolution. A fter the end of the follow -up phase there is no 
requirement to actively  collect TEAEs including deaths. The type of information that should be 
assessed and recorded b y the investigator for each TEAE is listed in Section 10.4.1.2. 
10.4.1.4 Expected TEAE s
Known TEAEs of radiographic or MRI contrast media may  occur following administration of 
gadobutrol . The majorit y ofTEAEs occur within 30 minutes of administration; this is the 
minimum period during which the patient should be under continuous supervision . The most 
common TEAEs after administration of gadobutrol are nausea, headache and dizziness. Other 
TEAEs that may  occur include (but are not limited to) taste perversion, paresthesia, vomiting, 
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 38of 60
hypersensitivity  reactions, dy spnea, ery thema, pruritus, rash, injection site reactions and feeling 
hot. 
For IV injection of gadobutrol, the routine precautions and supervision should be used as with 
any other radiographic or MRI  contrast medium . In very  rare cases, severe anaph ylactoid 
reactions or shock may  occur . Familiarit y with the practice of emergency procedures is essential 
for prompt, efficient action in the event of post injection TEAEs. Appropriate emergency  staff, 
drugs, and i nstruments (eg, endotracheal tube and ventilator) must be readily available . 
Symptoms such as itching skin, or a coughing fit may be the first signs of an anaphy lactoid 
reaction. Administration of the contrast medium must be discontinued immediately , and a ny 
complications treated according to generall y accepted clinical guidelines. 
The a dverse event rate and general safet y profile of gadobutrol is comparable to other Gd-based, 
approved MRI contrast agents (eg, gadoterate ).
10.4.1.5 Reporting of serious adverse even ts
The definition sof SAEs /TESAEs aregiven in Section 10.4.1.1. Each SAE / TESAE must be 
followed up until resolution or stabilization by  submission of updated reports to the designated 
recipient.
“Dea th” should not be recorded as a SAE / TESAE on the SAE / TEAE page . Instead, “death” is 
the outcome of underly ingSAE / TESAE (s).
For all SA Esthe sponsor has to carry  out a separate assessment for expectedness, seriousness and 
causal relationship to study  drug.
Investigator’s notification of the sponsor
All investigators will be thoroughly instructed and trained on all relevant aspects of the 
investigator’s reporting obligations for SAEs / TESAE s. This information, including all relevant 
contact details, is summarized in the investigator site file. This information will be updated as needed.
The investigator must report immediately  (within 24 hours of the investigator’s awareness) all 
SAEs / TESAE s occurring during the observation period defined in Section 10.4.1.3 to the 
recipient detailed in the instructions for SAE / TESAE reporting included in the I nvestigator File . 
For this, a SAE / TEAE page in the CRF as well as the complementary  pages provided in the 
Investigator File must be completed for each SAE /TESAE. 
All SAEs occurring after the protocol -defined observation period will be processed by  the 
sponsor according to all applicable regulations.
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 39of 60
Notification of the IECs / IRBs
Notification of the IECs / I RBs about all relevant events (e.g. TESAE s, suspected, unexpected, 
serious adverse reactions [SUSARs]) will be performed by  the sponsor /CRO and/or b y the 
investigator according to all applicable regulations.
Notification of the authorities
The processing and reporting of all relevant events (e.g. TESAE s, SUSARs) to the authoriti es
will be done by  the sponsor according to all applicable regulations.
Sponsor’s notification of the investigational siteThe sponsor /CRO will inform all investigational sites about reported relevant events (e.g. 
SUSARs) according to all applicable regula tions.
10.4.1.6 Expected adverse events
For this study , the applicable reference document sarethe current versions of the package 
insert /SmPC for each imaging agent .
The expectedness of TEAE s will be determined by the sponsor according to the applicable 
reference document and according to all local regulations.
10.5 Prospective blinded image evaluation and centralized procedures
Diagnostic efficacy  will be evaluated by  prospective evaluations of the blinded images in a 
centralized manner . The blinded readers will be independent radiologists who have not been 
involved in the clinical study . They  will be blinded to all patient history  and will not have any  
information about the study  center, detailed information about the sequence parameters, the 
application of the contra st agent, or the study  protocol . Further details on blinded image 
evaluation and centralized procedures will be provided in the I mage Review Charter by  GCIS .
10.5.1 Image handling and preparation
All image sets that are required in this protocol will be provided electronically  in DICOM format 
by the centers.
The images will be sent to the image core laboratory  GCIS, Berlin, where the images will be 
prepared for evaluation . Received images will be reviewed b y the core laboratory  for quality  
control with regard to clinical appropriateness and protocol adherence. If an issue is found, the 
core laboratory  or its representative will contact the investigator and attempt to correct it for 
future patients.
An audit trail will be maintained.All software for the image proc essing is standardized.
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 40of 60
10.5.2 Blinded reading evaluations
The blinded image evaluations will be performed centrall y at the image core laboratory b y 
independent radiologists experienced in CNS imaging who are not involved in the clinical portion 
of the study . A c ore-lab generated blinded read eCRF will be used to ensure that the images and 
the diagnostic findings are properl y aligned and to ensure that all questions are answered by  the 
blinded readers. 
The blinded read will be in three sessions . The first session will score the lesion variables for 
unenhanced and combined Agent 1 and a determination of malignant disease and confidence.Two weeks later –the same blinded read procedure will be followed for Agent 2. 
At a third session, the blinded readers will score apaired presentation of the t1w enhanced 
images forimage preference . 
Additional details will be provided in the Image Review Charter b y GC IS.
In case one of the readers cannot continue the reading (e.g. illness), a new read er will be selected 
andtrained. A separate blinded reading manual contains the details. 
Training will be provided for the reader before the blinded image evaluation in the completion of 
the eCRF, in the operation of the imaging work station (eg, window and leveling controls), and in 
the specific protocol language, such as the definition of the scores used for the imaging variables and image qualit y. A refresher training session may  be provided prior to each reading session . 
Refresher training sessions may  be provided as applicable. Reading sessions will be usually  
conducted in a remote setting (web based) with each reviewer separated from each other In case 
reading sessions will be conducted at centralized facilities it will be ensured that readers are monitored by  GCIS staff or qualified external personnel .
A core lab representative might be present at the time of the blinded read to answer technical 
questions initiated by  the readers such as use of equipment or completion of eCRFs. All 
interactions will be documented. All personnel present during a reading session will be blinded to 
image modality  assignment and other clinical data and will be subject to the applicable financial 
disclosure . The identity and the relationship to the sponsor of such personnel will be recorded.
Exceptionally  a case may be re -opened and re -evaluated due to an y circumstance that is 
significantl y impacting the correct reading process or interpretation of study images, e.g., 
erroneous com pletion of a case, any non -compliance issues, and additional site information 
delivered after the time of the original reading or technical issues. The responsible I maging 
Clinician will review such cases before authorizing a re- evaluation of the case, and onl y data that 
is directly  affected by  the respective error or circumstances should be subject to a reassessment 
by the Independent Central Reader. A thorough explanation and documentation will be provided 
within the I mage Evaluation Summary  Report.
Complete re -reads of all images and cases may only be permitted pri or to the primary  anal ysis 
when a reader has to be replaced due to non- compliance or systematic errors .
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 41of 60
If case s have to be re -assessed it will be documented in the audit trail. This documentation is 
enforced b y the image evaluation module (IEM) sy stem .
The blinded image evaluations may  take place in parallel with the conduct of the clinical trial . 
10.5.3 Technical prerequisites for blinded readings
10.5.3.1 Blinded image evaluation system
Blinded image evaluations will be conducted using full fidelit y digital images. The system ty pe 
and workstation details will be documented in an Imaging Review Charter provided b y the core 
laboratory  and maintained in the sponsor’s TMF . 
The number of screens needed for the blinded image evaluation will be adapted to the different 
readin g parts.
Standard functions at the image visualization sy stem will be available to the reader during the 
review sessions , eg.:
Ability  to change the image brightness and contrast (level/window) of all image material 
and screens
Ability  to move through the images of one set 
Ability  of image zoom and move
10.5.3.2 Electronic CRF design
An eCRF will be used for the electronic data capture of the evaluation results by  the blinded 
readers during the reading sessions as discussed in Section 10.5.2. The eCRF application allows 
for a logical progression design with a built- in plausibility  check according to the user 
requirements document, forcing the readers to answer the appropriate questions and auto-
checking for missing data. Once the blinded reader has completed a case, no further changes can be made b y the blinded reader . This process facilitates the efficient and timely  completion of the 
digital based image review . 
Each eCRF is developed based on the annotated CRF created b y the sponsor following the 
requirements of the central destination database . 
Adequate data transfer to the sponsor’s database is guaranteed and will be tested prior to the start of the blinded image evaluation.
The plausibility  check built into the eCRF will guarantee that:  
All entries will be made and checked according to logical plausibility   
The next case to be evaluated can onl y be started after the entries for the current case ha ve 
been finished.
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 42of 60
All data required b y the protocol are to be entered into the eCRF . A trained monitor from the core 
laboratory  may  be available to assist the reader in entering his/her appropriate answers into the 
eCRF fields. 
Once the reader has completed the appropriate section of the eCRF, he or she will be asked to 
enter a password in order to approve the eCRF case record . After approval, the entry  pages are 
locked and no further changes can be made . The eCRF will be signed by  the blinded reader 
imme diately  after each case . 
All evaluations will be stored in the sponsor’s central study  destination database for anal ysis. 
10.5.4 Randomization of image material
Each image set from a single patient will be assigned separate randomization numbers for each session.   
10.5.4.1 Independent blinded reader training
All readers will undergo training prior to the start of the blinded image evaluations . Training will 
be provided b y the core laboratory , GCIS . The training sessions will include a review of the 
appropriate stud y guidelines, a review of the image display  software, a review of the eCRF, and a 
review of teaching and training cases. A record of the training sessions will be maintained, with signatures and dates of the blinded readers and the personnel performing the tra ining . The 
training session data and images will be archived along with the images from the blinded evaluations. 
Teaching cases comprised of images not included in the actual image evaluation sessions will be 
reviewed with the readers, noting presentation of various radiologic findings. Additionally , the 
blinded readers will conduct a “mock” blinded image evaluation on training cases that will not be part of the stud y data. The training image evaluations will be identical to the actual image 
evaluations in process and will allow the blinded readers to work with the image review software 
and the eCRF . The training session will be conducted prior to the start of the actual blinded image 
evaluations. Results of the training sessions will be conjointly  reviewed with the readers prior to 
the start of the actual blinded image evaluations. 
10.5.4.2 Blinded image evaluation of the MRI
The blinded image evaluations are described in de tail in the IRC.
All readers will be completely  blinded with regard to patient data, clinica l information, center -
related and imaging -related information as well as details of the study  protocol . 
10.5.4.3 Quantitative contrast enhancement
Quantitative contrast enhancement estim ation will be performed using a n exploratory Overall 
Contrast Enhancement Estimation Algorithm. Results will be summarized by  MRI modality  
using descriptive statistics and confidence intervals.
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 43of 60
10.6 Appropriateness of procedures and measurements
The efficacy  and safet y measurements described above are widel y used and generall y accepted as 
reliable, accurate, and relevant . 
The comparison of the study  drug (gadobutrol) with an approved comparator product for 
noninferiority  reflects a reliable clinical and scientific technique to determine efficacy  and safe ty. 
The blinded MRI  reading procedure with independent radiologists is planned to minimize bias 
from the clinical stud y, because clinical investigators’ diagnoses might be influenced b y other 
clinical information they  might have received about the patient s. 
The safet y parameters evaluated in this study are routine clinical parameters and allow risk 
assessment of the investigational drug. 
11. Statistical methods and determination of sample size
11.1 General considerations
11.2   Statistical and analytical plans
11.2.1 General considerations
The primary  efficacy  analy ses of the 3 primary  efficacy  variables (visualization) will be done 
using the average (arithmetic mean) of the values of the 3 blinded readers . The anal ysis of these 
variables and the anal yses of the secondary eff icacy  variables will also be performed on the data 
from the 3 blinded readers individually . 
For border delineation, contrast enhancement, and internal morphology , there will be multiple 
values for each patient (ratings for multiple lesions). The average ( arithmetic mean) of these 
ratings will be used for the primary  and secondary  analy ses. To avoid using a scoring s ystem that 
rates the detection of fewer but more well- visualized lesions over the detection of more lesions, 
some of which may  be not so well visualized, the anal ysis will be performed using zero-filled 
averages of the ratings for each patient . 
In cases where the scans detect different number of lesions, enough zeros will be included with 
the scores for the modalities which detected fewer lesio ns to make the average for each modalit y 
based on the same number of scores. This zero -filled average will alway s reward the detection of 
extra lesions.
Demographic variables (age, race, sex, etc.) will be summarized using frequency  tables and 
descriptive statistics. Safety  variables will be summarized using descriptive statistics and frequency  tables.
All confidence intervals will be 2- sided, 95% intervals. 
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 44of 60
Statistical tests for superiority  will be 2- tailed, using the 0.05 level of significance . Any stat istical 
tests used for noninferiority  will be one sided tests using the 0.025 level of significance. 
11.3 Analysis sets
11.3.1 Definition of efficacy analysis set
Analy ses of efficacy  data will be performed using data from all patients for whom eCRF entries 
and image s are available for unenhanced MRI, combined unenhanced and gadobutrol- enhanced 
MRI , and combined unenhanced and gadoterate- enhanced MRI . This population will be the full 
analysis set (FAS).
Efficacy  anal yses will also be performed using data from those pa tients from the FAS who also 
fulfill all major provisions of this protocol. This set will be the per protocol anal ysis set (PPS). 
A patient will be excluded from the PPS for any  one of the following reasons:
1.The patient received a dose of gadobutrol that was less than 90% or greater than 110% of the 
assigned dose.
2. The patient received a dose of gadoterate that was less than 90% or greater than 110% of the 
assigned dose.
3.An obvious error in the MRI  procedure occurred either during the gadobutrol period or d uring 
the gadoterate period.
4. Pertinent images for the patient are damaged or lost.
11.3.1.1 Definition of safety analysis set
Analy sis of safet y data will be performed using all available data from all enrolled patients. 
11.4 Variables and planned statistical analyses
11.4.1 Primary efficacy variables
The 3primary  anal ysis variables are :  
Lesion border delineation
Degree of lesion contrast enhancement
Lesion internal morphology
For the 3 variables, the average (arithmetic mean) lesion score will be calculated for each patient 
based on the scores for each individual lesions in a given patient. 
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 45of 60
11.4.1.1   Primary efficacy analysis - visualization parameters
The primary  efficacy  analy sis is based on the data from the blinded readers’ evaluation of
3visualization parameters, whic h are evaluated in unenhanced and combined unenhanced and 
enhanced MR image sets. 
A successful primary  analy sis is a demonstration of noninferiorit y for the difference between 
unenhanced and combined gadobutrol and unenhanced and combined gadoterate enhan ced and 
unenhanced MRI to unenhanced MRI for the first 3 primary  visualization parameters. 
1. the contrast enhancement (measured on an ordinal 4- point scale);
2.the border delineation (measured on an ordinal 4 -point scale); 
3.the internal morphology  (measured on an ordinal 3 -point scale)
The anal ysis for three of these parameters (1, 2, and 3) will be performed on the mean of the 
values for the 3 blinded readers (blinded reader average). This anal ysis will be performed on the 
dataset including the patient aver age ratings for lesions.
For each parameter a noninferiority  hypothesis will be considered, where the comparison will 
relate to a reasonable portion (c=0.2) of the difference between combined unenhanced and 
gadoterate mean to unenhanced. The goal is to sh ow, that the loss in the visualization parameter 
(gadoterate - gadobutrol) is lower than a 0.2 times the combined gadoterate and unenhanced to 
unenhanced mean, which is equivalent to (gadobutrol – gadoterate) is greater than - 0.2 times the 
combined gadoter ate and unenhanced to unenhanced mean. “Mean” is the mean of the blinded 
reader averages.
The null and alternativ e hypotheses for noninferiority  are: 
H0: (gadobutrol – gadoterate)  ≤-0.2*(gadoterate –unenhanced), versus 
K0H1: (gadobutrol – gadoterate)  >-0.2*(gadoterate –unenhanced), 
where “(gadobutrol –gadoterate)” indicates the difference between combined unenhanced and 
gadobutrol mean to unenhanced mean minus the difference of combined unenhanced and 
gadoterate mean to unenhanced mean. The expression “(gadoterate – unenhanced)” indicates the 
difference between combined unenhanced and gadoterate mean to unenhanced mean.
The study  is considered successful if all 3 hy potheses related with the se co -primary  target 
variable s can be rejected each at a one-sided alpha of 0.025 or equivalentl y at a two- sided alpha 
of 0.05. Appropriate paired t-tests will be used.No ty pe I error adjustment for multiple comparisons is needed because tests on all 3variables 
must be significant t o demonstrate primary  efficacy . 
In addition 95% two-sided confidence intervals for the mean difference of the gadobutrol score 
and the gadoterate score will be calculated.
The primary  anal ysis will be performed using data from evaluations from lesions.
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 46of 60
11.4.2 Secondary efficacy variables
The secondary  efficacy  variables will be the evaluation of the detection of malignant disease . The 
evaluation of quantitative param eters will be performed by  GCI S and image quality  will be 
evaluated onl y by the blinded reader(s). 
The secondary  efficacy  variables are the :
Comparison of c ontrast enhancement utilizing an exploratory Overall Contrast 
Enhancement Estimation Algorithm.
Number of lesions identified (up to 10)
Identification of b enign or m alignant disease 
Conf idence in diagnosis 
Image qualit y
11.4.2.1 Overall Contrast Enhancement Estimation Algorithm
Quantitative contrast enhancement estim ation will be performed using a n exploratory Overall 
Contrast Enhancement Estimation Algorithm. Results will be summarized by  MRI modality  
using descriptive statistics and confidence intervals.
11.4.2.2 Number of lesions able to be identified
A confidence interval for the difference in the number of lesions detected by  the 2 contrast agents 
will be constructed. Noninferiorit y of number of lesions detected will be demonstrated using 
confidence intervals based on the t- distribution with a noninferiority margin of 0.35. 
11.4.2.3 Identification of benign or malignant disease
The investigator determines if the patient has benign or malignant disease. 
The presence or absence of malignant disease in each patient for both contrast agents will be 
determined b y the blinded readers, as well as the majority  blinded reader (at least 2 of 3 readers), 
and compared to the investigators’ assessment to calculate sensitivity  and specificit y for each 
drug. 
Sensitivity , specificity , and accuracy  for each drug will be compared using a McNemar ’s test 
with a noninferiorit y margin of 10 percent . 
11.4.2.4 Confidence in diagnosis —AMENDED
Frequency  tables for confidence responses (1 -4) for patients will be constructed for combined 
unenhanced and gadoterate-enhanced MRI, and combined unenhanced and gadobutrol- enhanced 
MRI . Descriptive statistics for the combined unenhanced and gadobutrol and gadoterate enhanced 
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 47of 60
MRI  and their difference will be generated . Confidence intervals for the differences will be 
generated.
11.4.2.5 Image quality
The blinded readers will evaluate relative image quality  of gadobutrol and gadoterate as 
described in Section 10.2.1.6.3 . 
After the data are unblinded, the 5 -point scale used by  the blinded readers will be translated into 
the following scale: 
-2 = Gadobutrol image is worse
-1 = Gadobutrol image is slightly  worse
0 = Images are the same
1 = Ga dobutrol image is slightly  better
2 = Gadobutrol image is better
Frequency  tables and descriptive statistics will be generated on these values, and the relative 
image qualities will be tested for equalit y using a Wilcoxon signed -rank test.
11.4.2.6 Analysis of sa fety variables —AMENDED
Frequencies of TEAE s will be tabulated by  contrast agent and the proportions of patients 
exhibiting each TEAE will be display ed. Tabulations will also be made for the body  system, 
intensity , and attribution corresponding to each T EAE. Separate tabulations will be made for 
serious TEAEs.
11.5 Determination of sample size
The determination of the sample size was based on the primary  noninferiority  test for the 
difference between unenhanced means and combined gadobutrol -enhanced and unenhanced 
means and combined gadobutrol -enhanced and unenhanced means to unenhanced means.
It considers all three primary  efficacy  visualization parameters. 
1.the contrast enhancement
2.the border delineation 
3.the internal morphology  
For each parameter a no n-inferiorit y hypothesis will be considered, where the comparison will 
relate to a reasonable portion of the difference between gadoterate and unenhanced. The goal is to 
show, that the loss in the visualization parameter (gadoterate -gadobutrol) is lower than a 
constant times the combined gadoterate and unenhanced to unenhanced.
The mean differences of combined gadobutrol and unenhanced to unenhanced, “(gadobutrol-
unenhanced)”, observed in the pivotal study 310123 for these parameters will be used for powe r 
calculation (1.29, 0.60, 0.61).
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 48of 60
The related statistical hypotheses read as follows:
H0: (gadobutrol - gadoterate) ≤ -0.2*(gadoterate –unenhanced) 
vs. 
K0H1:(gadobutrol –gadoterate )> -0.2*(gadoterate –unenhanced)
The study  is considered successful if all 3 hy potheses related with these co- primary  target 
variables c an be rejected at a one-sided alpha of 0.025 or equivalentl y at a two-sided alpha of 
0.05. Appropriate paired t-tests will be used.
Rejection of such a h ypothesis means that it is demonstrated that gadobutrol (at reduced dose) 
preserves at least 80% of the effect gadoterate /Dotarem has compared to unenhanced images.Enrolling 180 subjects allows for approximately  25% non-evaluable patients and guarantees 90% 
power for border delineation. For the remaining two variables the power will be close to 100% 
with this sample size. Hence also the overall power of this study  will be 90%.
No ty pe I error adjustment for multiple comparisons is needed because tests on all 3 variables 
must be significant to demonstrate primary  efficacy . 
12. Data handling and quality assurance
12.1 Data recording
The data collection tool for this study  will be a validated electronic data capture sy stem called 
RAVE. Subject data necessary  for anal ysis and reporting will be entered/ transmitted into a 
validated database or data sy stem (SAS). 
Data required according to this protocol will be recorded b y investigational site personnel via 
data entry  into the internet based electronic data capture (EDC) software sy stem RAVE, which 
has been licensed from Medidata Solutions Worldwide. RAVE has been validated b y Medidata 
Solutions Worldwide for use in Bay er’s clinical studies. RAVE allows for the application of 
software logic to set -up da ta entry  screens and data checks to ensure the completeness and 
accuracy  of the data entered by  the site personnel. The logic has been extensively  applied to 
ensure data are complete and reflect the clinical data requirements of the study . Data queries 
resulting from the application of the software logic are resolved b y the site personnel. The data 
are stored at a secure host facility  maintained b y Medidata Solutions Worldwide, and transferred 
by the CRO to Bay er’s internal computers via secure lines. 
All access to the RAVE system is through a password- protected security  system that is part of the 
RAVE software. All internal Bay er and external investigator site personnel as well as the CRO 
personnel seeking access must go through a thorough RAVE trainin g process before they  are 
granted access to RAVE for use in Bay er's clinical studies. Training records are maintained. 
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 49of 60
All personnel with access to the RAVE sy stem are supported by  a Service Desk staffed with 
trained personnel to answer questions and ensure access is maintained such that data entry  can 
proceed in a timely  manner. 
The RAVE Sy stem contains a sy stem -generated audit trail that captures any changes made to a 
data field, including who made the change, wh y the change was made and the date and time it 
was made. This information is available both at the investigator’s site and at Bay er. Data entries 
made in the RAVE EDC screens are supported b y source documents maintained for all subjects 
enrolled in this study .
Source documentation
The site must i mplement processes to ensure availability  of all required source documentation. 
Asource document checklist (not part of this protocol) will be used at the site to identify  the 
source data for key  data points collected and the monitor will work with the site to complete this.
It is the expectation of the sponsor that all data entered into the eCRF has source documentation 
available at the site . 
Data recorded from screening failuresAt minimum, the following data should be recorded in the CRF:
Demographic i nformation ( patient number; year of birth /age; sex; if applicable race / 
ethnicity )
Date of informed consent
Relevant inclusion/exclusion criteria
Reason for premature discontinuation
Date of last visit . 
These data will be transferred to the respective database.
For screening failures with a SAE / TESAE, the following data should be collected in the CRF in 
addition to the data specified above :
All information related to the SAE / TESAE such as: 
-TheSAE / TESAE itself
- Concomitant medication
-Medical histo ry
-Other information needed for SAE / TESAE complementary  page
12.2 Monitoring
In accordance with applicable regulations, GCP, and sponsor’s/CRO’s procedures, monitors will 
contact the site prior to the start of the stud y to review with the site staff the protocol, study 
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 50of 60
requirements, and their responsibilities to satisfy  regulatory ,ethical, and sponsor’s requirements. 
When reviewing data collection procedures, the discussion will also include identification and 
documentation of source data items.
Thesponsor /designee will monitor the site activity  to verify  that the:
Data are authe ntic, accurate and complete . 
Supporting data may  be requested (example: blood glucose readings to support a 
diagnosis of diabetes). 
Safety  and rights of patients are being protected
Study  is conducted in accordance with the currently  approved protocol 
(including stud y treatment being used in accordance with the protocol)
Any other study  agreements, GCP, and all applicable regulatory requirements are met.
The investigator and the head of the medical institution (where applicable) agrees to allow the 
monit or direct access to all relevant documents . Details will be provided in the Monitoring Plan.
12.3 Data processing
Data will be collected as described in Section 12.1. Clinical data management will be performed 
in accordance with applicable sponsor’s / CRO’s standards and data cleaning procedures. This is 
applicable for data recorded on CRF as well as for data from other sources.
For data coding (e.g. AEs /TEAE s, medication), internationally  recognized and accepted 
dictionaries will be used.
12.4 Missing data 
Not applicable
12.5 Audit and inspection
To ensure compliance with GCP and regulatory  requirements, a member of the sponsor’s (or a 
designated CRO’s) quality  assurance unit may  arrange to conduct an audit to assess the 
performance of the study at the study  site and of the study  documents originating there . The 
investigator/institution will be informed of the audit outcome.In addition, inspections by regulatory  health authority  representatives and IEC(s)/I RB(s) are 
possible . The investigator should notify  the sponsor immediately  of any  such inspection.
The investigator/institution agrees to allow the auditor or inspector direct access to all relevant 
documents and allocate his/her time and the time of his/her staff to the auditor/inspector to discuss findings and an y issues. Audits and inspections may  occur at an y time during or after 
completion of the study .
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 51of 60
12.6 Archiving
Essential documents shall be archived safel y and securel y in such a way that ensures that they  are 
readil y available upon authorities’ request.
Patient (hospital) files will be archived according to local regulations and in accordance with the 
maximum period of time permitted by  the hospital, institu tion or private practice . Where the 
archiving procedures do not meet the minimum timelines required b y the sponsor (i.e.15 years 
after the end of stud y), alternative arrangements must be made to ensure the availability  of the 
source documents for the required period.
The investigator/institution notifies the sponsor if the archival arrangements change 
(e.g. relocation or transfer of ownership).
The investigator site file is not to be destroyed without the sponsor’s approval.
The contract with the investigat or/institution will contain all regulations relevant for the stud y 
center.
13. Ethical and legal aspects
13.1 Investigator(s) and other study personnel
All other study  personnel not included in this section are identified in a separate personnel list 
(not part of this clinical study  protocol) as appropriate . This list will be updated as needed; an 
abbreviated version with personnel relevant for the centers will be available in each center’s 
investigator site file.
Whenever the term ‘investigator’ is noted in the pr otocol text, it may  refer to either the principal 
investigator at the site, or an appropriatel y qualified, trained and delegated individual of the 
investigational site.The principal investigator of each center must sign the protocol signature page and must receive 
all required external approvals (e.g. health authority, ethics committee, sponsor) before patient
recruitment may  start at the respective center. Likewise, all amendments to the protocol must be 
signed b y the principal investigator and must have received all required external approvals before 
coming into effect at the respective center.A complete list of all participating centers and their investigators, as well as all required signature 
documents, will be maintained in the sponsor’s study  file.
The global sponsor of this study  is identified on the title page of this protocol. If required b y local 
law, local co- sponsors will be nominated; they  will be identified on the respective country -
specific signature pages.
13.2 Funding and financial disclosure
Funding
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 52of 60
This study  will be funded by  its sponsor.
Financial disclosure 
Each investigator (including principal and/or an y sub investigators) who is directly  involved in 
the treatment or evaluation of research patients has to provide a financial disclosure a ccording to 
all applicable legal requirements . All relevant documentation will be filed in the trial master file.
13.3 Ethical and legal conduct of the study
The procedures set out in this protocol, pertaining to the conduct, evaluation, and documentation 
of this study , are designed to ensure that the sponsor and investigator abide by  Good Clinical 
Practice (GCP) guidelines and the guiding principles detailed i n the Declaration of Helsinki. 
The study  will also be carried out in keeping with applicable local law (s) and regulation(s).
Documented approval from appropriate IEC(s)/IRBs will be obtained for all participating centers/countries before start of the study, according to GCP, local laws, regulations and organizations . When necessary , an extension, amendment or renewal of the I EC/IRB approval 
must be obtained and also forwarded to the sponsor . The responsible unit (e.g. IEC/I RB, head of 
the study  center/medical institution) must supply  to the sponsor, upon request, a list of the 
IEC/IRB members involved in the vote and a statement to confirm that the I EC/IRB is organized 
and operates according to GCP and applicable laws and regulations.
Strict adherence to all specifications laid down in this protocol is required for all aspects of study  
conduct; the investigator may  not modify  or alter the procedures described in this protocol . 
Modifications to the study  protocol will not be implemented by  either the sponsor or the 
investigator without agreement by  both parties . However, the investigator or the sponsor may  
implement a deviation from, or a change of, the protocol to eliminate an immediate hazard(s) to 
the trial patient s without prior IEC/I RB/sponsor approval/favorable opinion . As soon as possible, 
the implemented deviation or change, the reasons for it and if appropriate the proposed protocol 
amendment should be submitted to the I EC/I RB/head of medical institution/sponsor . Any  
deviations from the protocol must be explained and documented b y the investigator.
13.4 Patient information and consent
All relevant informa tion on the study  will be summarized in an integrated patient information 
sheet and informed consent form provided b y the sponsor or the study center . A sample patient
information and informed consent form is provided as a document separate to this protoco l.
Based on this patient information sheet, the investigator or designee will explain all relevant 
aspects of the stud y to each patient , prior to his/her entry  into the study  (i.e. before an y 
examinations and procedures associated with the selection for th e stud y are performed or an y 
study -specific data is recorded on study -specific forms).
The investigator will also mention that written approval of the IRB/IEC has been obtained.
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 53of 60
Each patient will be informed about the following aspects of premature withdra wal:
Each patient has the right to withdraw from the study  at any  time without any  disadvantage 
and without having to provide reasons for this decision. 
The patient ’s data that have been collected until the time of withdrawal will be retained and 
statistically  anal yzed in accordance with the statistical anal ysis plan. 
Patient- specific data on the basis of material obtained before withdrawal may be generated 
after wi thdrawal (e.g. image reading, anal ysis of biological specimen such as blood, urine or 
tissues); these data would also be retained and statistically  anal yzed in accordance with the 
statistical analy sis plan. The patient has the right to object to the genera tion and processing of 
this post -withdrawal data. The patient ’s oral objection may  be documented in the patient ’s 
source data.
Each patient will have ample time and opportunity  to ask questions.
Only  if the patient voluntarily  agrees to sign the informed c onsent form and has done so, may  
he/she enter the study . Additionally , the investigator will personally  sign and date the form . The 
patient / legal representative or prox y consenter will receive a cop y of the signed and dated form.
The signed informed consent statement is to remain in the investigator site file or, if locall y 
required, in the patient’s note/file of the medical institution.
In the event that informed consent is obtained on the date that baseline study procedures are 
performed, the study  reco rd or patient ´s clinical record must clearl y show that informed consent 
was obtained prior to these procedures.
The informed consent form and an y other written information provided to patients will be revised 
whenever important new information becomes avai lable that may  be relevant to the patient ’s 
consent, or there is an amendment to the protocol that necessitates a change to the content of the 
patient information and / or the written informed consent form . The investigator will inform the 
patient of changes in a timely  manner and will ask the patient to confirm his/her participation in 
the study  by signing the revised informed consent form . Any revised written informed consent 
form and written information must receive the IEC/I RB`s approval / favorable opinion in advance 
of use.
13.5 Publication policy and use of data
The sponsor has made the information regarding the study  protocol publicly  available on the 
internet at www.clinicaltrials.gov. 
All data and results and all intellectual propert y rights i n the data and results derived from the 
study  will be the property  of the sponsor who may  utilize them in various way s, such as for 
submission to government regulatory  authorities or disclosure to other investigators.
Regarding public disclosure of stud y results, the sponsor will fulfill its obligations according to 
all applicable laws and regulations . The sponsor is interested in the publication of the results of 
every  study  it performs . 
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 54of 60
The sponsor recognizes the right of the investigator to publish the results upon completion of the 
study . However, the investigator, whilst free to utilize study  data derived from his/her center for 
scientific purposes, must obtain written consent of the sponsor on the intended publication 
manuscript before its submission. To this end, the investigator must send a draft of the 
publication manuscript to the sponsor within a time period specified in the contract . The sponsor 
will review the manuscript promptly  and will discuss its content with the investigator to reach a 
mutu ally agreeable final manuscript. 
13.6 Compensation for health damage of patient s / insurance
The sponsor maintains clinical trial insurance coverage for this study  in accordance with the laws 
and regulations of the country  in which the study  is performed.
13.7 Conf identiality
All records identify ing the patient will be kept confidential and, to the extent permitted by  the 
applicable laws and/or regulations, will not be made publicly available.
Patient names will not be supplied to the sponsor. Only  the patient numbe r will be recorded in the 
CRF, and if the patient name appears on an y other document (e.g. pathologist report), it must be 
obliterated before a cop y of the document is supplied to the sponsor. Study  findings stored on a 
computer will be stored in accordance with local data protection laws . As part of the informed 
consent process, the patients will be informed in writing that representatives of the sponsor, 
IEC/IRB, or regulatory  authorities may  inspect their medical records to verify  the information 
collect ed, and that all personal information made available for inspection will be handled in 
strictest confidence and in accordance with local data protection laws.If the results of the stud y are published, the patient’s identity  will remain confidential.
The i nvestigator will maintain a list to enable patient s to be identified.
14. Reference list 
Not applicable
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 55of 60
15. Protocol amendments
15.1 Amendment 1 — 26 MAR 2019
Editorial note
In the sections on changes to the protocol text, all protocol sections affected by  the respective 
amendment are detailed; the sequence of the sections follows the structure of the most recent 
previous protocol version . As applicable, changes to the protocol text are highlighted as follows:
Editing of an existing portion : Comparative presenta tion of “old text” versus “new text”, 
with “old text” referring to the most recent previous protocol version . Deletions are 
crossed out in the “old text” . Additions are underlined in the “new text”.
In general, c orrection of typos or omissions are not highlighted. However, t hroughout the 
protocol, the designation of the alternative hy pothesis has been changed from K 0to H 1to align 
the protocol with the terminology  used in the SAP and with the general standard for designation
of the alternative h ypothes is. It is not considered to be a protocol change but is a correction. 
15.1.1 Overview of changes to the study
Section 10.2.1.1 MRI  Equipment —This section was changed to reflect changes in MRI  
field strength in common use and to permit either the previousl y specified 1.5 and the 
newer 3.0 field strength and to provide greater flexibility  based on the study center’s 
available MRI equipment. 
Section 10.2.1.2  Pulse sequences — This section was changed to recommend that 
T1w spin echo/FSE acquisition should be per formed in 2D mode.
Section 10.2.1.6.1 Quantitative contrast enhancement estimation — Upto 10 lesions” 
hasto be removed because the quantitative contrast enhancement estimation algorithm 
will not be applied to a single lesion or up to 10 lesions, becaus e it is a software 
evaluation result for a complete image. 
Section 11.4.2.4 Confidence in diagnosis —This section has been modified to clarify  
that f requency  tables for confidence responses will not be constructed for unenhanced 
MRI  alone. 
Section 11.4.2.6  Analy sis of safet y variables —This section was changed to remove 
thereference to McNemar's tests and/or related confidence intervals , reflecting a changed 
analysis plan. 
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 56of 60
15.1.2 Modification 1: Section 10.2.1.1  MRI equipment
The modified text is:
The procedure will be performed using either a 1.5 or a 3.0 Tesla MRI scanner that can perform 
the required pulse sequences (see Section 10.2.1.2) with a dedicated head coil . The manufacture r, 
model, software version, and field strength of the MRI  device will be recorded in the eCRF. The 
same scanner and required pulse sequences must be used for both the gadoterate and gadobutrol 
enhanced MRI’s. The same field strength (either 1.5 or 3.0) mu st be used for both scans. Mixed field strength scans 
are not permitted. In addition, T1w enhanced sequences must be performed at or near the same post- dose time point 
(4-10 mins) for each study  drug (gadoterate and gadobutrol).
Affected sections: No othe r sections.
15.1.3 Modification 2:  Section 10.2.1.2 . Pulse Sequences
The modified text is:The same parameter setting must be used for unenhanced T1w images and for contrast -enhanced 
T1w images in each patient. T1w spin echo/FSE acquisition should be performed in 2D mode.
The required pulse sequences for gadobutrol and gadoterate are:  
Unenhanced (axial and sagittal image presentation for brain)
oT1w spin-echo /FSE images of the whole brain -axial
oFluid Attenuated Inversion Recovery  (FLAI R) of the whole brain –axial
oOptional: T2w spin- echo images of the whole brain – sagittal or axial
Contrast -enhanced (axial and coronal image presentation for brain)
oT1w spin echo/ FSE images of the whole brain
General considerationsoThe MR scanner should NOT be actively  retuned after the unenhanced sequences  
Deviations from the specified MRI  procedure will be recorded in the eCRF . 
Affected sections: No other sections.
15.1.4 Modification 3: Section 10.2.1.2.1  Sequence parameters for brai n imaging
The modified text is:
The recommended sequence parameters for brain imaging is display ed below in Table: 10 -2.
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 57of 60
Table 10-2:     Orientation parallel to the planum sphenoidale (only for axial)
T2 SE/FSE T1 FLAIR
Plane Sagittal or Axial Axial or Coronal Axial
Pulse Sequence Spin echo /FSE Spin echo /FSE IR
Patient position Supine Supine Supine
Coil Head Head Head
Slice thick/spacing 3-5 skip 0-1.5 3-5skip 0-1.5 3-5 skip 0-1.5
Frequenc y ≥256 ≥256 ≥256
Phase ≥256 ≥256 ≥128
Nex ≥2 ≥2 ≥1
Affected sections: No other sections.
15.1.5 Modification 4: Section 10.2.1.6.1   Quantitative contrast enhancement
estimation
The modified text is:
Quantitative contrast enhancement estim ation will be performed using an exploratory Overall 
Contrast Enhancement Estimation A lgorithm . Descriptive statistics will be presented for each 
study  drug (gadoterate and gadobutrol) . Results will be summarized by  MRI modalit y using . Up 
to 10 lesions will be identified. 
Affected sections: No other sections.
15.1.6 Modification 5:  Section 11.4 .2.4  Confidence in diagnosis
The modified text is:Frequency  tables for confidence responses (1 -4) for patients will be constructed for unenhanced 
MRI , combined unenhanced and gadoterate -enhanced MRI, and combined unenhanced and 
gadobutrol -enhanced MRI . Descriptive statistics for the combined unenhanced and gadobutrol 
and gadoterate enhanced MRI  and their difference from unenhanced MRI will be generated . 
Confidence intervals for the differences will be generated.Affected sections: No other sections.
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 58of 60
15.1.7 Modification 6:  Section 11.4.2.6   Analysis of safety variables
The m odified text is:
Frequencies of TEAE s will be tabulated b y contrast agent and the proportions of patients 
exhibiting each TEAE will be display ed. Tabulations will also be made for the body  system, 
intensity , and attribution corresponding to each TEAE . Separate tabulations will be made for 
serious TEAE s . McNemar's tests and/or related confidence intervals will be used to assess the 
significance of the differences in incidence rates between the agents . 
Affected sections: No other sections.
16. Appendices
Appendix 1:  Volume of Gadobutrol 0. 075mmol/kg b y Body Weight
Appendix 2:  Volume of Gadoterate 0.1 mmol/kg by  Body  Weight
Clinical Study  Protocol
No. BAY No. 86-4875/ IMPACT no. 19773  
26 MAR 2019 Version no. 2.0   Page: 59of 60
Appendix 1:  Volume of Gadobutrol 0. 075mmol/kg by Body Weight
Body Weight (kg)Volume of Gadobutrol 
(mL)Body Weight (kg)Volume of Gadobutrol 
(mL)
45 3.4 79 5.9
46 3.5 80 6
47 3.5 81 6.1
48 3.6 82 6.2
49 3.7 83 6.2
50 3.8 84 6.3
51 3.8 85 6.4
52 3.9 86 6.5
53 4 87 6.5
54 4.1 88 6.6
55 4.1 89 6.7
56 4.2 90 6.8
57 4.3 91 6.8
58 4.4 92 6.9
59 4.4 93 7
60 4.5 94 7.1
61 4.6 95 7.1
62 4.7 96 7.2
63 4.7 97 7.3
64 4.8 98 7.4
65 4.9 99 7.4
66 5 100 7.5
67 5 101 7.6
68 5.1 102 7.7
69 5.2 103 7.7
70 5.3 104 7.8
71 5.3 105 7.9
72 5.4 106 8
73 5.5 107 8
74 5.6 108 8.1
75 5.6 109 8.2
76 5.7 110 8.3
77 5.8 115 8.6
78 5.9 120 9
Clinical Study  Protocol
No. BAY No. 86-4875 / IMPACT no.19773   
26 MAR 2019    Version no. 2.0 Page: 60of 60
Appendix 2:  Volume of Gadoterate 0.1 mmol/kg by Body Weight
Body Weight (kg)Volume of Gadoterate 
(mL)Body Weight (kg)Volume of Gadoterate 
(mL)
45 9.0 79 15.8
46 9.2 80 16.0
47 9.4 81 16.2
48 9.6 82 16.4
49 9.8 83 16.6
50 10.0 84 16.8
51 10.2 85 17.0
52 10.4 86 17.2
53 10.6 87 17.4
54 10.8 88 17.6
55 11.0 89 17.8
56 11.2 90 18.0
57 11.4 91 18.2
58 11.6 92 18.4
59 11.8 93 18.6
60 12.0 94 18.8
61 12.2 95 19.0
62 12.4 96 19.2
63 12.6 97 19.4
64 12.8 98 19.6
65 13.0 99 19.8
66 13.2 100 20.0
67 13.4 101 20.2
68 13.6 102 20.4
69 13.8 103 20.6
70 14.0 104 20.8
71 14.2 105 21.0
72 14.4 106 21.2
73 14.6 107 21.4
74 14.8 108 21.6
75 15.0 109 21.8
76 15.2 110 22.0
77 15.4 115 23.0
78 15.6 120 24.0